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ON THE COVER: An image from a negative-space 3D printed model 
of the ventricular and cisternal system in the brain obtained from 
an MRI analysis and labeled with voice-activated LED lights. This 
image was produced by Cullen Fleming, MSIV, while doing research 
in neuroradiology under the guidance of research advisor Ramin 
Javan, MD, associate professor of radiology. 
Photos like Flemings, capturing the beauty and intricacy of 
science, are featured annually in the George Washington University 
(GW) School of Medicine and Health Sciences (SMHS) Art of Science 
Contest. The competition began in 2018 as a means of highlighting 
the research that SMHS medical students, graduate students, and 
postdoctoral fellows are conducting. 
Each year prizes are awarded for the top entries and the winning 
images are displayed in Ross Hall, alongside those from previous 
years. 
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GW MEDICAL STUDENT RESEARCH 
FOURTH-YEAR MEDICAL STUDENT DARA BAKER, BS ’16, 
was awarded a fellowship as part of the National Institutes 
of Health (NIH) Medical Research Scholars Program. The 
year-long research immersion program fosters career 
development among budding physician scientists. Baker is 
using induced pluripotent stem cell technology to develop 
retinal epithelial cells to treat degenerative eye diseases 
under the mentorship of Kapil Bharti, PhD, senior investiga 
tor at the National Eye Institute at the NIH. 
In 2018, Baker received the William H. Beaumont Medi 
cal Society Student Research Awards for her abstract, The 
Role of DFMO in Helicobacter Pylori Infection: Modulation 
of ROS Response. In 2015, she received the Luther Rice Un 
dergraduate Research Fellowship through the GW Colum 
bian College of Arts and Sciences. 
Robert Miller, PhD, GW vice president for research and 
senior associate dean for research at SMHS, presented 
Sarah McCormack, MSIV, with the 2019 Doris DeFord 
Speck and George Speck Endowed Prize  
METEOR Program 
The Mentored Experience to Expand Opportunities in 
Research (METEOR) program is a competitive fellowship 
for underrepresented-in-medicine students. Students 
are supported for a six-week, pre-matriculation research 
summer and enroll in the research track. Participants also 
have the opportunity to work with a clinical and translational 
researcher who will serve as a mentor during their time 
in medical school, complete a second summer research 
internship after Year 1, and conduct a research elective 
during the third year of medical school. 
https://tinyurl.com/y86oxwmb 
Richard Simons, MD, senior associate dean for MD 
programs and professor of medicine at SMHS, 
presents the 2019 Walter Freeman Research Award for 
best research paper to (from left) Tina Boortalary, MD 
’19, (left) and Alastair Fritchen Murray, MD ’19, (right)  
GW Research Showcase, formerly GW Research Days, is a one-day event 
highlighting the breadth of innovation and creativity across all disciplines at GW
This event invites students and trainees to present their work and compete for 
top honors  Participants have the option of showcasing their research through 
interactive exhibits, in addition to poster presentations  
r 
J 
~---- --
:i W RESEARCH DAYS 
--
THE LAZARUS FAMILY SCHOLARSHIP PROGRAM 
Christina Pugliese, MS IV, The program provides piv-
and Sowmya Mangipudi otal experiences for future 
were the 2019 Lazarus Family leaders in health care, annu-
Scholarship recipients. The ally enabling one or more 
program, established by students to pursue a project 
Gerald Lazarus, MD, class of or program. Students apply 
’63, and Audrey Jakubowski in the spring of their second 
Lazarus, PhD, supports medi- year of medical school, and 
cal students as they pursue scholarship winners receive 
extraordinary educational funding for their remaining 
opportunities in health care. years of medical school. 
RESEARCH SCHOLARLY CONCENTRATION 
Each year, roughly 50 students elect to participate 
in the Clinical and Translational 
Research Scholarly 
Concentration. The program 
promotes mentored 
research for students 
during the summer 
between MSI and MSII, 
and enables them to attend 
research lectures and follow-
up with research scholarship. 
For details, see smhs.gwu.edu/oso/ 
track-program/ clinical-and-translational-research 
Former Beaumont Society Co-Presidents, and current third-year medical Students, 
Neil Almeida (far left) and Abby Pepin (far right) presented the annual William 
Beaumont Research Award for the top medical student abstracts to 2019 winners 
(from second left) Maria Cerezo, Neil Almeida, and Sharjeel Chaudry during 
“Research Days at GW” 2019  
REHEMA THOMAS is only in her 
second-year MD student, but she 
already has a head start on a spe 
cialzation in radiation oncology. 
During the summer of 2019, Thom 
as participated in the prestigious 
American Society for Radiation On 
cology’s (ASTRO) Minority Summer 
Fellowship. 
“Radiation oncology is a feld 
that’s lacking in diversity, and that is 
something I want to make a change 
in,” she said. “I want to make a dif 
ference in these outcomes because 
everyone deserves an equal chance 
at survival and beating cancer.” 
During her summer, Thomas 
worked with ASTRO member Curti 
land Deville, MD, clinical director of 
radiation oncology at Johns Hop 
kins Kimmel Cancer Center at Sibley 
Memorial Hospital, on the use of 
photon and proton therapies in soft 
tissue sarcomas. 
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 Letters: 
Letter from the Presidents 
As the co-presidents of the William 
H. Beaumont Medical Research
Honors Society, we proudly present
the 2020 edition of Fusion, the of-
cial medical research publication of
The George Washington University 
(GW) School of Medicine and Health
Sciences (SMHS). Fusion is an entirely
student run publication that serves
as a platform for medical students to 
share their work with the GW com-
munity. The fourteenth edition of
Fusion received a record number of
submissions spanning a broad range
of research areas, including basic sci-
ence, clinical research, translational 
research, biomedical engineering,
quality improvement, public health
and policy, education, and clinical
practice innovation. 
This past year has been an exciting
time for the GW research commu-
nity. The GW Strategic Initiative for 
improving the Research Ecosystem
has set signifcant change in motion 
with four main goals: increasing
support for faculty investigators,
enhancing GW’s research reputation 
by promoting university-led discov-
eries, aligning the missions of the
research and academic enterprises,
and enriching the student research
experience by increasing access to fac-
ulty investigators. Additionally, the 
Andrea Klein, MSII 
Hira Mohyuddin, MSII 
current leadership of Beaumont has
spearheaded novel programs designed
to provide new medical students with 
a structured path towards research
success during medical school. Our
most signifcant new program consists
of a lecture and workshop series on
navigating the research community,
obtaining funding, and organizing a 
research project. 
We wou ld l ike to tha n k our 
mentors David Leitenberg MD,
PhD, director of immunology in the 
Department of Laboratory Medicine 
at Children's National Hospital and
associate professor of microbiology,
immunology, and tropical medicine
at SMHS; and Alison Hall, PhD,
associate dean for research workforce
development at SMHS, for their guid-
ance as senior researchers and advi-
sors for the Fusion journal. We are
grateful for the eforts of the executive
and editorial board members (listed
on the table of contents) and their
contributions to the journal. 
We hope you enjoy this edition of 
Fusion and that you consider contrib-
uting next year! 
Andrea Klein MSII 
Hira Mohyuddin, MSII 
Co-Presidents of the William H  Beaumont 
Medical Research Honor Society 
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Letter from the Editors 
Scientific discovery and experimentation
advance patient care and shape the way phy-
sicians practice. With an array of scholarly
concentrations available to students at the
George Washington University (GW) School 
of Medicine and Health Sciences (SMHS),
our classmates advance the feld of medicine
in every aspect, from improving health care in 
low-resource regions to medical innovation and
policy writing, and everything in between. As 
participants in these concentrations, medical
students are tasked with going beyond the
preclinical curriculum and addressing the
problems of today’s health care system. This
formative appreciation for scientifc discovery 
is key to deepening our knowledge and changing
the way we — as the next generation of physi-
cians — treat, cure, advocate for, and support 
our patients.
According to the Association of American
Medical Colleges, the average pre-medical stu-
dent matriculates with 1,251 hours of research.
GW SMHS students are able to continue devel-
oping these research skills at the professional
level in a variety of DC health care settings
including: GW SMHS, Children’s National
Hospital, Washington DC Veterans Affairs
Medical Center, and the National Institutes of
Health. Early research experiences allow our
students to be better prepared for careers in
academia and show substantial interest in their
chosen feld to support a strong residency appli-
cation. Given the time constraints of medical
school, seeing a project through from conception
to publication is no easy feat, and one that should
be celebrated. Additionally, early involvement
enables the student to be involved in clinical
domains not previously explored and discover
their true interests. Finding one’s niche can be a
winding and roundabout process, where faculty
support can help a student not only develop
research skills, but clarity of career interest.
As junior Fusion journal editors, we are
delighted to highlight the diverse research
initiatives unique to GW SMHS and driven
by the strong intellectual curiosity present on 
our campus. Along with the research oppor-
tunities at GW SMHS, Fusion provides yet
another opportunity for student involvement
in all aspects of the research process including 
the art of presentation, manuscript writing,
and presentation. Participation in research is
benefcial for both the personal and professional
development of our medical students, but even 
more so, for the better health for our society. 
Health care is an ever-changing feld of practice
with advances in medicine, expanded evidence 
sources, new treatment options, and changing 
governmental regulations and models of care. 
Early experiences in research equip our students
with the ability to navigate this complex terrain
and serve as leaders in the future. 
Zach Falk, MSI
Aneka Khilnani, MSI
Zoe Shancer , MSI
Muhammed el Shatanofy, MSI 
Co-Directors of Fusion 
Zachary Falk, MSI 
Aneka Khilnani, MSI 
Zoe Shancer, MSI 
Muhammed
el Shatanofy, MSI 
6 Fusion | 2020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
       
 
 
   
 
 
 
 
 
 
 
 
 
 
    
 
 
    
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 Letters: 
Faculty Advisor’s Perspective 
As the faculty advisor for this year’s
issue of Fusion, it is an honor to con-
tribute my thoughts about medical
education and research.  As I’ve
become more involved with medical 
student teaching over the last several
years, I am continually struck by the
diversity of student interests and
backgrounds that each class brings to
The George Washington University
School of Medicine. The students that
are admitted to the MD program at the
George Washington University School
of Medicine and Health Sciences
(SMHS) have already achieved a sig-
nifcant level of academic success, but
have also developed unique interests
that set them apart as individuals.  It
is critical that, as students progress
through medical school and post-
graduate training, there be oppor-
tunities to preserve and foster the
development of these existing and new
unique interests. “Fusion” is a superb
forum to celebrate some of the more
individualized talents and interests of
our students outside of the classroom. 
Most students that enter medical
school have a curiosity and enthu-
siasm about how the complexities
of biological systems work and how
this relates to clinical care.  And just
as importantly, many of our students
have a strong interest in the critical
role that public health systems play
locally, nationally, and globally in
impacting health. It is critical that this
enthusiasm be supported and allowed
to grow, as it will inform and influ-
ence student career paths and impact
future attitudes toward patient care in
multiple and often unforeseen ways.
The students involved in research
and who have contributed to this issue
of Fusion have a special role.  You serve
as role models to your peers by demon-
strating a commitment to intellectual
curiosity as you progress through
medical school training.
Medical students at GW have mul-
tiple opportunities to pursue research
experiences and complete a scholarly
project outside of the required cur-
riculum.  Most commonly this involves
participating in one of the nine schol-
arly concentrations that provide an
academic structure and mentoring
help for students throughout the
four years of medical school.  In
order to support these endeavors, stu-
dents are also encouraged to compete
for external, nationally competitive
research fellowships, as well as our
own internal fellowship awards that 
provide valuable fnancial support for
the students while they pursue summer
projects. Our students’ accomplish-
ments are demonstrated by the many
poster presentations at GW Medical
Student Research day, presentations 
at more specialized national and inter-
national meetings, and publications in
peer-reviewed journals. 
As is evident in the following
pages, there are many ways to achieve
a meaningful research experience that
David Leitenberg MD, PhD, associate
professor of microbiology, immunology,
and tropical medicine at SMHS, and director
of immunology in the Department of
Laboratory Medicine at Children's National
Hospital 
span a broad range of interests and
disciplines, including basic and transla-
tional science, clinical research, health
policy and public health research,
and education-related research.  An
additional essential component of a
successful student research project is
the dedication and enthusiastic guid-
ance provided by our faculty mentors,
both here at GW and at our DC area
partner institutions, as well as outside
academic centers nationally and inter-
nationally. We applaud and thank you
for your eforts.
BASIC SCIENCE
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 Basic Sciences / Infectious Disease: 
Select gp120 V2 Domain Specifc Antibodies Derived from HIV 
and SIV Infection and Vaccination Inhibit gp120 Binding to α β
Matthew Liu, 
MSII 
ADVISORS: 
James Arthos, PhD,1 
Anthony S  Fauci, 
MD1 
1 National Institute 
of Allergy and Infectious Diseases, National 
Institutes of Health 
The GI tract is preferentially targeted 
during acute/early HIV-1 infection. 
The basis for preferential targeting 
of gut tissues is not well defined. 
Recombinant proteins and synthetic 
peptides derived from HIV and SIV 
gp120 bind directly to integrin α4β7, a 
gut-homing receptor.1 
To cha racter ize the k i netic 
gp120-α4β7 binding interaction, we 
developed a novel surface-plasmon 
resonance (SPR) based assay. In the 
presence of a physiologic 1mM MnCl2 
bufer, soluble α4β7 demonstrated com-
parable afnities for surfaces coated 
with either MAdCA M-Ig fusion 
protein or recombinant A244 gp120. 
When MnCl2 was removed, afnity 
for both MAdCAM and gp120 fell 
below the detection limit of this assay 
(Figure 1). This observation suggests 
that gp120 is likely to engage α4β7 only 
on cells with an enhanced potential to 
trafc to the gut. We replaced A244 
gp120 with a synthetic cyclic 42 amino 
acid peptide fragment (cV2) derived 
from the V2 domain of 92TH023 gp120 
(subtype A/E), whose sequence is 
nearly identical to that of A244 gp120 
V2. The afnity of this peptide (cV2 
92TH023) for α4β7 was close to that of 
A244 gp120, demonstrating that cV2 is 
sufcient to mediate the high-afnity 
interaction shown in Figure 1. When 
4 7 
FIGURE 1: Specifc affnity of α4β7 for HIV gp120, MAdCAM and SIV gp120 
A) Sensorgram of increasing concentrations (2-fold) of soluble α4β7 passed over 
surface-immobilized MAdCAM in the presence of 1 mM MnCl2 for 120 sec, followed 
by a 120 sec washout/dissociation phase  Mass of bound α4β7 (y-axis) expressed 
as response units (RU) Affnity expressed as KD (nM) is shown B) Same as in panel 
A, with immobilized A244 gp120  C) Same as in panel A with immobilized MAdCAM 
in the absence of divalent cations  D) Same as in panel A with immobilized A244 
gp120 in the absence of divalent cations  E) Same as in panel A with immobilized cV2 
92TH023 peptide  F) Same as in panel A with immobilized 92TH023 cV2 peptide and 
soluble α4β1 as the analyte  Each sensorgram is representative of three independent 
measurements of each analyte-ligand interaction  
we replaced α4β7 with α4β1, affinity 
for cV2 92TH023 was reduced by 
>8000 -fold, demonstrating binding 
specifcity and the fact that V2, like 
M AdCA M, preferentia l ly binds 
to α β7.4 
However, V2 peptides can adopt 
either α helical or β strand structures.2 
This is the case for a crystal struc-
ture of a linear V2 peptide derived 
from HIV isolate 92TH023 gp120 
that complexes with mAb CH58 in a 
helical structure (Figure 2).3 CH58 is 
a weakly-neutralizing mAb that was 
generated from an uninfected immu-
nized individual who participated in 
the Rv144 vaccine trial.4 It recognizes 
an epitope that maps within a short 
region of V2 (AA 168–181) identifed 
by sieve analysis as sites of vaccine elic-
ited immune pressure in the RV144 
trial (Figure 2). Other V2-specific 
m Abs that recognize str uctures 
in this same region include mAb 
MK16C2 and mAb CAP228-16H, 
which were generated from a HIV-
infected subject and gp120 immu-
nized rabbit, respectively. We evalu-
ated the ability of each of these mAbs 
to inhibit α4β7interactions with V2 
Continued on p. 8 
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Continued from p. 7 
using a cell-based adhesion assay 
where RPMI8866 cells expressing 
α4β7 on the cell surface were allowed to 
adhere to synthetic V2 cyclic peptides. 
mAbs 2B4 and VRC01 were employed 
as specifcity controls. mAbs CH58 
and CAP228-16H, which recognize 
a helical structure, inhibited α4β7 
adhesion to V2 by >90% while mAb 
830A, which shows preference for the 
β strand, failed to show detectable 
interference (Figure 2). 
In this study, we characterized 
the physical interaction between the 
HIV envelope and α4β7, reasoning 
that such information could provide 
valuable insight regarding the role of 
α4β7-expressing cells in HIV patho-
genesis. We fnd that a subset of HIV 
and SIV V2 antibodies derived from 
both infected subjects and vaccine 
recipients can efectively block V2 α4β7 
interactions. Several of the vaccine-
elicited weakly neutralizing mAbs 
have been linked with protection 
from infection. Rather than binding 
to the closed trimeric spike that is the 
primary target of broadly neutralizing 
antibodies, these mAbs recognize an 
alternative conformation of the V2 
region. This suggests that α4β7 also rec-
ognizes an alternative form of V2 that 
is conserved in both HIV and SIV. 
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Schizophrenia is an idiopathic neuro-
psychiatric condition with heteroge-
neous clinical presentations.1 For this 
reason, it is imperative to determine 
novel therapeutic targets and bio-
logical pathways mediating the patho-
genesis of this disorder. Schizophrenia 
has been associated with chronic 
Toxoplasma gondii infection in 
numerous studies.1 Reactivation 
of latent Toxoplasma gondii infec-
tion in animals results from antigen 
specific CD8+ T-cell exhaustion 
and is reported as a complication of 
Toxoplasma gondii infection.2 The 
objective of this study was to deter-
mine whether Toxoplasma gondii 
(T. gondii) infection increases brain 
T-cell infltrates as a potential trigger 
for the pathogenesis and behavioral 
alterations in schizophrenia. Namely, 
whether there would be an increase in 
the amount of T cells in brain tissue 
following infection with T. gondii 
and whether this difered from simple 
disruption of the blood brain barrier 
with lipopolysaccharide (LPS). 
This study was conducted in a 
translational research lab. A total 
of 11 C57BL/6 mice were divided 
into three groups. One group (n=2, 
12 weeks old) was injected with LPS 
22 hours prior to sacrifce and brain 
collection. Successful blood brain 
FIGURE 1: 
barrier disruption has been reported 
between 18-24 hours following injec-
tion with LPS.3 The second group 
(n=4, 7 weeks old) was orally infected 
with ova transgenic parasites 5 weeks 
prior to sacrifce and brain collection. 
The control group (n=5, 8-12 weeks 
old) was not infected with T. gondii 
or injected with LPS prior to sacrifce 
and brain collection. Brain tissue was 
digested, stained with antibodies to 
determine the amount of CD4+, CD8+, 
CD3+/CD45+, and CD11b+ cells, and 
prepared for Flow Cytometry. Flow 
Cytometry results were analyzed with 
FlowJo and GraphPad Prism software. 
The data from this study was ana-
lyzed with GraphPad Prism software. 
One-way ANOVAs were performed 
to compare the percentage of CD4+, 
CD8+, CD3+/CD45+, and CD11b+ 
cel ls from brain tissue bet ween 
the diferent groups. The T. gondii 
infected group exhibited the highest 
average percentage of CD3+/CD45+ 
cells when compared to the LPS 
(p<0.0001) and control (p<0.0001) 
groups. The T. gondii group also 
exhibited the highest percentage 
of CD11b+ cel ls when compared 
to the control (p<0.0001) and LPS 
(p=0.0003) groups (Figure 1). Of the 
CD3+/CD45+ cells, the percentage 
of CD8+ and CD4+ was determined. 
The T. gondii group exhibited the 
highest percentage of CD8+ cells 
when compared to controls (p=0.0377) 
however there was no signifcant dif-
ference between the T. gondii and 
LPS groups or the control group and 
the LPS group. The control group 
exhibited the highest percentage of 
CD4+ cells when compared to the T. 
gondii group (p=0.0080) and the LPS 
group (p=0.0035) (Figure 2). 
Compared to LPS and control 
groups, T. gondii infected mice exhib-
ited the highest percentage of CD3+/ 
CD45+ and CD11b+ cells. Additionally, 
when compared to the control group, 
the T. gondii group exhibited a higher 
percentage of CD8+ cells, which 
Continued on p. 10 
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suggests that T. gondii infection 
enhances CD8+ T-cell infltration and 
may lead to enhanced T-cell exhaus-
tion and the associated neurobio-
logical and behavioral abnormalities 
in schizophrenia. In the future, we 
hope to further investigate whether 
schizophrenia-like brain and behav-
ioral changes occur in mice infected 
with Toxoplasma gondii as a result of 
PD-1 mediated CD8+ T-cell exhaus-
tion. In addition, we hope to deter-
mine whether antibodies targeting 
the PD-1 molecule will prevent these 
changes. 
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Type 1 diabetes (T1D) is an autoim-
mune disease characterized by pan-
creatic β-cell destruction, resulting 
in insulin defciency. The pancreas is 
anatomically unique because while it 
is predominantly an exocrine gland, 
1-2% of it is composed of endocrine 
islets of Langerhans. Previous studies 
have focused on the role of the endo-
crine pancreas on regulation of exo-
crine function. However, there is 
evidence that the exocrine pancreas 
also plays a role in regulating the 
endocrine pancreas, yet the mecha-
nism remains unclear.1 We previ-
ously showed that co-incubation of Following a fve-day incubation, islets (p>0.05), those expressing glucagon 
murine islets in vitro with trypsinogen were harvested, dispersed and stained showed a 1.2% decrease (p>0.05), 
induced β-cell proliferation. In this for insulin, glucagon, and Ki67 expres- and those expressing Ki67 showed a 
study, we report the potential role of sion in order to identify β-cells, α-cells 1.6% increase (p>0.05). However, the 
another component of the exocrine and proliferative cell 
pancreatic secretome, trypsin inhib- populations, respec- These data suggest that the pancreatic exocrine 
itor, on inducing pancreatic β-cells tively. Cells were ana-
into a proliferative phenotype in vitro. lyzed by flow cytom- secretome may play a role in regulating islet 
Islets were isolated from C57BL/6 etry with the gating 
mice by a midline incision, cannula- scheme i l lustrated cell phenotype, which may pave a new avenue 
tion of the common bile duct with in Figure 1. The data 
collagenase, and purifcation using a from three separate in T1D therapy via modulating β-cell mass. 
Ficoll gradient centrifugation. Islets experiments were ana-
were then plated in RPMI 1640/10% lyzed using unpaired, two-tailed percent of islet cells expressing both 
FBS/ 1% penicillin streptomycin and t-test using Prism software (Figure insulin and Ki67 following trypsin 
incubated at 37.5o C/ 5.0% CO2. After 2). Compared to islets incubated in inhibitor incubation was signifcantly 
overnight recovery, islets were placed media alone, the percent of islet cells 
in media supplemented with 1/3 uL 1 incubated in trypsin inhibitor, showed Continued on p. 12 
FIGURE 1: Flow cytometry gating scheme  Data was gated in the following order: 
cells, single cells, live cells Then, live cells were gated for insulin, glucagon, and Ki67 
expression, respectively  Finally, a double gate was created by gating for Ki67 expression 
on top of the insulin gate  
ug/uL trypsin inhibitor (Sigma T0256). a 7% increase in insulin expression 
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increased by 4.4% compared to islet 
cells in media alone (p<0.01) (Figure 
2). These data suggest that the pan-
creatic exocrine secretome may play 
a role in regulating islet cell pheno-
type, which may pave a new avenue 
in T1D therapy via modulating β-cell 
mass. Future studies will explore the 
functionality of islets treated in vitro 
with exocrine pancreatic secretome. 
REFERENCES: 
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FIGURE 2: Cumulative data analysis from all three experiments showing no 
statistical signifcance iin the changes of percentage of cells that express insulin (A), 
glucagon (B), and Ki67 (C) between trypsin inhibitor treated islets and RPMI 1640 
culture medium controls, except concurrent insulin and Ki67 expression with p<0 01 
Continued on p. 12 
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Signif icant neurodevelopmental 
delay is emerging as one of the 
most important current challenges 
for patients with congenital heart 
disease (CHD).  Previous clinical 
studies demonstrate that reduced 
oxygen delivery due to CHD results 
in subnormal brain development.1,2 
The piglet brain is a powerful new tool 
to study human brain development. 
We hypothesize that studies using 
the piglet model of chronic cerebral 
hypoxia will allow us to understand 
the underlying cellular events of 
chronic hypoxia in perpetuating 
neurodevelopmenta l da mage in 
children with CHD.3 This study 
aims to evaluate the efect of chronic 
hypoxia on piglet brains through 
histological, DTI (diffusion tensor 
ima g ing ) a nd NODDI (neu r ite 
orientation dispersion and difusion 
imaging ) ana lyses to determine 
the regional diference in the brain 
damage in CHD. 
Piglets were exposed to either 
chronic hypoxia (10.5% O2: H(x) 
group, n=12) or sham-hypoxia (21% 
O2: N(x) group: n=12) from P3 to P14. 
Six piglets from each group were 
euthanized at day 14 (2-week N(x) and 
2-week H(x)), and another 6 piglets 
from each group were subjected to 
grow under normal oxygen conditions 
from day 14 to six weeks of age (6-week 
N(x) and 6-week H(x)). Brains were 
extracted from piglets and examined 
using 1) immunohistochemical assays 
(Olig2+, CC1, PDGFR-α) to assess 
the cellularity alterations in white 
matter following chronic hypoxia, 
and 2) DTI (including fractional 
anisotropy (FA), axial diffusivity 
(AD), radial diffusivity (RD), and 
mean difusivity (MD) images) and 
NODDI (includ ing N DI, ODI, 
and KAPPA images) neuroimaging 
techniques.1,2 MRI-based piglet 
brain atlases were applied on DTI 
and NODDI images to evaluate 
structural differences between Hx 
and Nx brains. 
Two-week Nx brains revealed a 
significant increase in the density 
of CC1-positive cells compared to 
2-week Hx brains in white matter. 
A significant increase of fractional 
anisotropy (FA) intensity was also 
obser ved in the peripheral white 
matter of Nx brains compared to Hx 
brains at 2 weeks (Figure 1). Although 
the diferences of FA intensity in the 
peripheral white matter disappeared 
between Nx and Hx at six weeks, 
central deep white matter revealed a 
signifcant decrease in FA intensity in 
Hx brains vs Nx brains at six weeks. 
Radial diffusivity (RD) mapping 
demonstrated a signifcant increase in 
the right anterior cortex in 2-week Nx 
brains compared to 2-week Hx brains. 
Orientation Dispersion Index (ODI) 
mapping also revealed a signifcant 
increase in central white matter 
regions between two weeks Nx and 
Hx (Figure 2). KAPPA mapping a 
significant increase in central gray 
matter regions between two weeks 
Nx and Hx. 
The results reveal diferent cellular 
and microstructural alterations after 
chronic hypoxia between deep and 
peripheral regions in the piglet white 
matter. Studies using this model 
can provide important data needed 
to better interpret human imaging 
studies. 
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Diffuse midline glioma ( DMG), 
including diffuse intrinsic pontine 
glioma (DIPG), constitutes up to 
20% of pediatric brain cancer and 
has a median survival of less than 
one year.1 We have identifed a novel 
HL A-A*02:01-restricted neoa n-
tigen epitope encompassing the 
H3.3K27M mutation and imple-
mented a pilot clinical trial through 
the Pacifc Pediatric Neuro-Oncology 
Consortium (PNOC007). Newly 
diagnosed DIPG patients who are 
FIGURE 1: A multifaceted analysis incorporating patient-specifc myeloid HLA-A2+ and H3.3K27M+ underwent 
subpopulation proportions as well as H3 3K27M-specifc CD8+ T-cells was conducted radiation therapy, and then received 
to elucidate potential trends that may exist between immune composition and the H3.3K27M peptide vaccine and 
clinical outcomes While not statistically signifcant, patients with less than 25% of tetanus toxoid (TT) peptide emulsi-
myeloid cells phenotyped as monocytic myeloid-derived suppressor cells (Mgroup) 
fied in Montanide in combination at baseline were found to have a hazard ratio (HR) of 0 10 (CI = 0 01-1 00, p-value = 
with poly-ICLC every three weeks for 0 051)  Furthermore, non-statistically signifcant inverse trends between the baseline 
a total of 24 weeks. proportions of myeloid cells phenotyped as early myeloid-derived suppressor cells 
Our objective is to characterize (Egroup) and H3 3K27M-reactive CD8+ T-cells (DexGroup) were observed  
vaccine-induced H3.3K27M-specifc 
T-cell subpopulations in peripheral 
blood mononuclear cells through correlated with activation, memory, novel H3.3K27M-specifc dextramer-
the evaluation of surface markers and exhaustion phenotypes utilizing a based mass cytometr y method.2 
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Through this approach, the temporal 
expansion of vaccine-reactive CD8+ 
T-cells was observed in all patients (n 
= 4) who completed a minimum of 18 
weeks of the study. These T-cells were 
subsequently stratifed into discrete 
clusters on a tSNE plot using canonical 
CD8+ T-cell markers. Resultant clus-
ters were further classifed by their 
expression profles, revealing distinct 
efector memory and exhausted sub-
populations. Chronological moni-
toring of these groups indicates the 
time course-dependent development 
and persistence of vaccine-reactive 
exhausted and efector memory CD8+ 
T-cells in 75% of patients analyzed. 
Fu r thermore, a compa rative 
analysis of myeloid subpopulations 
revea led a n inverse correlation 
between the expansion of monocytic 
myeloid-derived suppressor cells 
(M-MDSCs) and length of stay on 
the vaccine.3 Future plans include the 
analysis of regulatory T-cells (Tregs) 
and MDSCs of all enrolled patients 
to further investigate the relationship 
between the length of stay on the study 
and prevalence of immunosuppres-
sive populations. This methodology 
offers insight into the progression 
of vaccine-induced patient immune 
responses and exhibits promise as a 
platform that may be extrapolated to 
other immunotherapies. 
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FIGURE 2: A Kaplan-Meier survival curve was conducted to elucidate 
the potential clinical implications of monocytic myeloid-derived 
suppressor cells (M-MDSCs). Patients were divided into cohorts 
containing greater (Mgroup=High) and less (Mgroup=Low) than 
25% of myeloid cells phenotyped as M-MDSCs, revealing a trend of 
Mgroup=Low experiencing longer overall survival post-diagnosis, though 
not statistically signifcant (p-value = 0.085). 
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Prostate cancer continues to be the 
most common non-cutaneous solid 
tumor diagnosed in men in the United 
States, with 13,000 new diagnoses 
among A merican ma le veterans 
annually, and is the second leading 
cause of death among American male 
veterans.1,2 In an attempt to tailor 
treatments to each patient, specifc 
mutations have been evaluated in 
tumors via targeted next generation 
sequencing (NGS).3 Although studies 
using NGS in clinically aggressive 
prostate cancers have been done in 
the civilian population,4,5 similar 
studies in veterans have not been per-
formed to date. The purpose of this 
study was to characterize the genetic 
profiles of prostate cancer among 
a veteran population treated at the 
U.S. Department of Veterans Afairs 
Greater Los Angeles Healthcare 
System. 
In this retrospective cohort study, 
we analyzed NGS data collected 
between August 2006 and September 
2018. Archival or fresh prostate cancer 
tissue from 81 veterans (76 primary 
tumors, 5 metastases) underwent tar-
geted sequencing via the Personalis 
TABLE: PATIENT AND DISEASE CHARACTERISTICS 
Characteristics N = 81 
Median age, years (range) 68 
Gleason Score 
Gleason 6 1 
Gleason 7 27 
Gleason 8 19 
Gleason 9 25 
Gleason 10 7 
Gleason  unknown 2 
Site of metastasis at sequencing 
bone 28 
LN 15 
viscera 6 
Race 
White 30 
African American 37 
Hispanic/Latin American 8 
Asian/Pacifc Islander American 3 
Native American 1 
Declined to answer 2 
ACE CancerPlus® next generation 
sequencing platform. The sequencing 
panel covers 181 genes frequently 
mutated in cancers. Clinically relevant 
genomic alterations were defned as 
changes in copy number or mutations 
(fusions, deletions, rearrangements, 
truncations) within established onco-
gene/tumor suppressor pathways 
such as DNA damage repair (DDR), 
PI3K/AKT, p53, MAPK, WNT and 
AR regulation. Patient demographic 
statistics and frequencies of muta-
tions from the patient samples were 
tabulated. 
The table presents the baseline 
characteristics of 81 prostate cancer 
patients in our study. A majority of 
patients had Gleason scores between 
seven and 10. At time of biopsy, the 
median age was 68, with metastases 
noted in the bone, lymph nodes, and 
viscera. Forty three percent of tissue 
samples from primary tumors had 
clinically relevant genomic altera-
tions, including 6.2% with activating 
mutations in MAPK pathway mem-
bers (KRAS, ERBB2, or BRAF), 
3.7% with somatic mutations in DDR 
genes (BRCA2 or ATR), 7.3% with 
mutations in TP53 or RB1, 4.9% in 
APC, 1.2% in the WNT pathway 
(CTNNB1), 3.7% with mutations in 
the PI3K/AKT pathway (PIK3R1 or 
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AKT1), 3.7% with PTEN deletions, 
and 22.2% with alterations involving 
an AR regulated gene (SLC45A3 or 
TMPRSS) (Figure). Of the fve meta-
static tumor samples sequenced, one 
had a mutation in TP53 and one had 
an ETS gene fusion (Figure). 
In this study, we demonstrate 
that NGS of prostate cancers in the 
veteran population is feasible and 
may help facilitate their enrollment 
in future precision oncology trials. 
Interestingly, only 43% of this cohort’s 
tumors had detectable mutations, 
which is markedly diferent from other 
published data on prostate cancer 
where virtually 100% of patients have 
a detectable genetic lesion.4 This dif-
ference in detected mutations may be 
due to genetic lesions that are present, 
but not recognized by the Personalis 
platform. Additionally, these tumors 
may be driven by epigenetic altera-
tions that would require another 
approach to elucidate such events. 
Lastly, the genetic alterations of vet-
erans’ prostate cancer may be distinct 
from those in the civilian population, 
and are not readily detected by plat-
forms such as Personalis. Thus, larger 
FIGURE: Each vertical row represents one of 81 patients, and each horizontal row 
represents the corresponding detected mutated gene Vertical rows 37, 54, 61, 74, and 
80 represent sequenced genes from the fve biopsied metastatic sites while the rest 
represent genes from primary tumors  
data sets, along with more robust 
sequencing platforms, are required for 
clarifcation. 
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Chordoma is a rare and aggressive 
bone sarcoma of the skull base and 
sacrum. Due to its indolent nature, 
it often presents late into the disease 
progression. More than 30% of chor-
doma patients develop metastases, 
and ten-year survival rates remain 
approximately 50 - 60%. Though 
Although research has been increas-
ingly active in this area to understand 
the tumor biology of chordoma, there 
are no currently FDA-approved treat-
ments, leaving surgical resection and 
radiation as the mainstays of treat-
ment. Introducing The development 
of new therapies for chordoma ulti-
mately represents a substantial unmet 
medical need.1 
We explored ribavirin, an anti-
viral drug approved to treat hepatitis 
C, as a potential therapeutic for 
chordoma. This drug was considered 
given its prior evidence of anti-tumor 
efects against other cancer types and 
also due to preliminary data from an 
assay indicating ribavirin directly 
decreases growth of chordoma cell 
lines. Ribavirin is known to target 
and inhibit eukaryotic initiation 
factor 4E (eIF4E), a regulatory sub-
unit of the eIF4F complex that is 
known to be overexpressed in 30% 
of all cancers.2 In studies examining 
the M A PK pathway, which can 
FIGURE 1: Proliferation assay of treated UCH-1 cells  
remove inhibitory control of eIF4E-
Binding Protein 1 (4EBP1) on eIF4E 
via phosphorylation, almost all human 
chordomas showed immunoreactivity 
to not only eIF4E, but also to its 
phosphorylated form (p-eIF4E) and 
the phosphorylated form of 4EBP1, 
indicating its potential value as a 
new target for chordoma treatment.3 
However, as ribavirin has multiple 
cell targets, we also investigated 
DZNeP, a small-molecule inhibitor 
of S-adenosylmethionine-dependent 
methyltransferase activity. This 
includes inhibition of the histone 
methyltransferase EZH2, which has 
been implicated as a driver in a myriad 
of cancer types. Ribavirin also has 
been demonstrated to inhibit EZH2; 
we investigated the therapeutic poten-
tial of ribavirin and DZNeP in parallel 
in order to explore the comparative 
effectiveness of multiple potential 
targets in chordoma.4 
Sacral and clival chordoma cell 
lines (U-CH1 and UM-Chor1, respec-
tively) were utilized for in vitro experi-
ments and treated with DZNeP 
and ribavirin in various micromolar 
concentrations. U-CH1 was assessed 
for cell growth via Cell Counting Kit 
8 and proliferation assays, where cells 
were manually counted over three 
timepoints. UM-Chor1 was assessed 
for cell death (apoptosis) via f low 
cytometry with AnnexinV (AnnV) 
and Propidium Iodide (PI) staining. 
AnnV+/PI- staining indicates early 
apoptosis; AnnV+/PI+ indicates late 
apoptosis. Additionally, clonogenic 
assays were performed in both cell 
lines. 
In proliferation assays of the 
U-CH1 cell line treated with ribavirin 
or DZNeP, a visible trend of steadily 
lower cell count over eight days for 
both ribavirin and DZNeP-treated 
cells was shown seen (Figure 1). Flow 
cytometry in the UM-Chor 1 cell line 
demonstrated a signifcant increase 
in the number of AnnexinV+ cells 
for those treated with DZNeP, and a 
trend toward apoptosis in cells treated 
with ribavirin (Figure 2). Clonogenic 
assays showed a trend toward decrease 
in clonogenic potential of U-CH1 but 
not UM-Chor1 cells when treated 
with ribavirin, while a decreased clo-
nogenic potential was demonstrated 
in both cell lines when treated with 
DZNeP. 
The use of ribavirin may present 
some currently mixed results in 
efectiveness against chordoma, but 
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this warrants further investigation 
as monotherapy and in combination 
therapy regimens with other treat-
ment modalities, including radiation. 
The promising preliminary results 
using DZNeP imply that its targets 
may be a viable means for chordoma 
treatment. Further investigation into 
DZNeP through in vivo experiments 
may provide evidence pivotal for the 
treatment of this devastating cancer. 
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Immune checkpoint blockade (ICB) 
has shown outstanding clinical suc-
cess in the treatment of melanoma; 
however, a signifcant proportion of 
patients develop resistance or do not 
respond to ICB.1 New focus has been 
placed on improving the efcacy of 
ICB through the inclusion of molecu-
larly targeted agents such as histone 
deacetylase 6 inhibitors (HDAC6is). 
Histone deacetylases (HDACs) are 
important epigenetic modulators 
of gene expression that have been 
FIGURE 1: Functional characterization of next-generation HDAC6 inhibitors in 
comparison to Nexturastat A  SM1 Cells were cultured and treated with inhibitor ranging 
in concentration from 0 1 mM-25 0 mM for 24 hours  (a) HDAC6i potency was quantifed 
using the HDAC-GloTM I/II Assay  (b) Compound cytotoxicity was evaluated using the 
CellToxTM Green Cytotoxicity Assay  (c–d) Cells were lysed in RIPA buffer with 1X protease 
and phosphatase inhibitor for the evaluation of inhibitor specifcity by immunoblot  
Acetylated turbilin and histone 3 expression were analyzed by densitometry
identified as prime cancer therapy 
ta rgets. HDAC in hibitors have 
already shown signifcant anti-cancer 
efects through a primarily cytotoxic 
function;2 however, recent studies also 
suggest that some inhibitors take on 
Continued on p. 20 
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a non-canonical role as modulators 
of immune-regulated signaling path-
ways.3 For example, highly selective 
HDAC6is, including Nexturastat A 
(Next A), are able to heighten tumor 
immunogenicity and immune surveil-
lance by modulating the expression 
of a variety of immunoregulatory 
proteins and shaping the infamma-
tory status within tumor microen-
vironments.3 These non-canonical 
f unctions ma ke HDAC6is idea l 
compounds for the potentiation of 
immunotherapeutic agents. This 
study characterizes the functional 
properties of three next-generation 
HDAC6is in comparison to NextA, 
as well as their non-canonical actions 
related to immune-regulated path-
ways and other non-cytotoxic cellular 
functions. Additionally, we aim to 
complement functional characteriza-
tion with in vivo and ex vivo studies 
to determine anti-tumor activity in 
syngeneic melanoma models. 
Three next-generation HDAC6is 
(SS-5-54, SS-5-55, SS-5-56), were com-
pared to NextA at concentrations 
from 0.1 µM to 25 µM over 24 hours 
in vitro using murine melanoma SM1 
cells. The potency and cytotoxicity 
of these inhibitors were quantified 
through HDAC - Glo™ I/ II a nd 
CellTox™ Green Cytotoxicity assays, 
respectively. Immunoblotting was 
used to assess specifcity with acety-
lated tubulin as a positive readout 
and acetylated histone 3 as a negative-
unspecific readout. Highly specific 
HDAC6is were further evaluated 
for anti-tumoral activity and immu-
nomodulatory effects in vivo using 
SM1 tumor-bearing C57BL/6 mice 
challenged with HDAC6i, αPD1, 
and combination therapy. Tumors 
were observed over 2 weeks, and sub-
sequently resected, processed, and 
FIGURE 2: Compound SS-5-55 functions as an immunological agent  
analyzed using fow cytometry against 
a comprehensive immune cell surface 
marker panel. 
We found that SS-5-55 best dem-
onstrated characteristics of an ideal 
1c & d). This specifcity refects an 
essential characteristic of selective 
HDAC6 inhibition consistent with a 
non-canonical, immunomodulatory 
function. SS-5-55 demonstrated a 14.1-
Our results support the characterization of SS-5-55 as a minimally 
cytotoxic, selective HDAC6i that functions as an immunological 
priming agent capable of potentiating αPD1 immunotherapies. 
HDAC6 inhibitor with selectivity 
comparable to NextA. SS-5-55 exhib-
ited signifcant potency beginning at 
low concentrations (2.5 – 5 µM) (Figure 
1a), while maintaining low cyto-
toxicity above 10 µM where NextA 
becomes exceed ing ly c y totox ic 
(Figure 1b). Densitometric analysis 
of Western blots revealed that SS-5-55 
increased acetylation of α-tubulin 
in a dose-dependent fashion, but 
not acetylation of Histone 3 (Figure 
fold increase in acetyl-α-tubulin at 10 
µM, whereas NextA led to a 7.2-fold 
increase. 
Tumor-bea ring m ice treated 
with a combination of αPD1 and 
SS-5-55 showed significant reduc-
tion in tumor volume compared to 
individual therapies alone (data not 
shown). Combination therapy also 
demonstrated significant changes 
in the tumor microenvironment, 
exhibiting an increase in infltrating 
BASIC SCIENCE
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cytotoxic T-cell and natural killer 
T-cell composition, as well as cyto-
toxic T cell efector memory (Figure 
2). Furthermore, combination therapy 
and SS-5-55 therapy alone demon-
strated a signifcant increase in M1/ 
M2 macrophage phenotype ratio; 
pro-tumorigenic M2 macrophages 
were significantly reduced, while 
pro-infammatory M1 macrophages 
persisted. 
Our results support the char-
acterization of SS-5-55 as a mini-
mally cytotoxic, selective HDAC6i 
that functions as an immunological 
priming agent capable of potentiating 
αPD1 immunotherapies. Further 
studies are needed to elucidate the 
compound’s specific mechanism of 
action. 
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With an estimated 117,470 new cases 
of B-cell malignancies in the United 
States in 2016, B-cell malignancies 
are currently treated with phos-
phoinositide-3 kinase delta (PI3KD) 
inhibitors, such as idelalisib, a p110δ
isoform-specific PI3K inhibitor.1, 
2 Idelalisib, in combination with 
rituximab, is US FDA approved for 
the treatment of relapsed or refrac-
tory chronic lymphocytic leukemia 
(CLL). 3 However, despite idelalisib 
being an effective treatment for 
B-cell malignancies, 28% of patients 
are resistant to idelalisib therapy.2 
The mechanism of this resistance is 
unknown. Our laboratory’s proposed 
mechanism of resistance is aberrant 
over-expression of the short iso-
form of PI3KD (PI3KCD-S), formed 
through alternative RNA splicing 
(AS) in idelalisib-resistant patients. 
FIGUREC1: P110δ-S kinase activity is resistant to new PI3K inhibitors copanlisib and 
buparlisib a The long isofor exhibits does-dependant sensitivity (inhibition) to currently 
available PI3K inhibitors used clinically to treat B-cell malignancies, including copanlisib 
and buparlisib b The short isoform is resistant to currently available PI3K inhibitors, 
including copanlisib and buparlisib
AS is a cellular post-transcriptional is associated with greater resistance 
regulatory process that produces to idelalisib. 
alternative mRNA transcripts, which Previous cell-free kinase assays 
encode distinct protein isoforms.4 in our laboratory have demonstrated 
We hypothesize that a higher ratio of 
short to long (S/L) isoforms of PI3KD Continued on p. 22 
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each cell line  Malignant B-cell lines, JeKo-1 and JVM2, exhibiting the highest S/L ratio 
were resistant to the apoptotic and anti-prolierative effects of idelalisib
Continued from p. 21 
that the recombinant short PI3KD 
isoform, but not the long isoform 
(PI3KCD-L), is resistant to the PI3KD 
inhibitors idelalisib, umbralisib, and 
duvelisib. We tested two additional 
PI3KD inhibitors, copanlisib and 
buparlisib, recently shown to be efec-
tive in treating B-cell malignancies. 
Both inhibitors were likewise inefec-
tive in reducing activity of PI3KCD-S, 
while potently inhibiting activity of 
PI3KCD-L. 
and Maver cells showed greater sen-
sitivity to idelalisib, while JeKo-1 and 
JVM-2 showed greater resistance to 
idelalisib. These results suggest that 
the expression level of PI3KCD-S 
may have an important role in confer-
ring varying degrees of resistance to 
PI3KD inhibitors. 
With these results, we correlated 
these varying degrees of resistance to 
idelalisib with S/L expression ratios 
measured by RT-PCR. Malignant 
B-cell lines JeKo-1 and JVM-2, the 
two cell lines that were resistant to 
Malignant B-cell lines JeKo-1 and JVM-2, the two cell lines that were 
resistant to the apoptotic and anti-proliferative effects of idelalisib, 
exhibited higher S/L ratios, while the two cell lines that were sensitive 
to the effects of idelalisib, Granta and Maver, showed lower S/L ratios. 
In the second phase of the experi-
ment, we tested the sensitivity of 
ma ligna nt B -cel l l ines ( JeKo-1, 
Maver-1, Granta, JVM-2), which 
express varying levels of the short 
and long mRNA variants of PI3KD, 
to idelalisib using Caspase-glo® 3/7 
assay to measure apoptosis and BrdU 
assay to measure proliferation. The 
results demonstrate that the four cell 
lines possess varying sensitivities to 
idelalisib. More specifcally, Granta 
the apoptotic and anti-proliferative 
efects of idelalisib, exhibited higher 
S/L ratios, while the two cell lines that 
were sensitive to the efects of idelal-
isib, Granta and Maver, showed lower 
S/L ratios. While these results are 
preliminary, a high S/L ratio is shown 
to be associated with resistance to the 
apoptotic and anti-proliferative efects 
of idelalisib, supporting our hypoth-
esis that aberrant over-expression of 
PI3KCD-S contributes to primary and 
acquired resistance in patients with 
B-cell malignancies. 
In the future, we aim to accom-
plish two additional tasks: 1) employ 
CRISPR to knock-out the PI3KD 
gene in malignant B-cell lines followed 
by ectopic over-expression of either 
the long or short variants of PI3KD, 
and 2) procure retrospective human 
patient specimens to measure the S/L 
expression ratio of PI3KD and corre-
late these fndings to idelalisib resis-
tance. We hypothesize that patients 
displaying resistance to idelalisib will 
present with malignant specimens 
exhibiting a high S/L expression 
ratio of PI3KD. Conversely, patients 
displaying sensitivity to idelalisib will 
present with malignant specimens 
exhibiting a low S/L expression ratio of 
PI3KD. These fndings emphasize the 
role of PI3KCD-S in B-cell malignan-
cies resistant to PI3KD inhibitors and 
the necessity for precision medicine in 
the clinical setting to improve therapy 
for patients with B-cell cancers. 
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In the United States, approximately 
45% of pregnancies are unintended, 
which is among the highest rates 
i n the developed world. L ong-
Acting Reversible Contraceptives 
(LARC) are the most efective form 
of contraception a nd therefore 
are a cr ucia l piece of achieving 
reproductive health equity for low-
income popu lations.1 Med ica id 
covers approximately 19.4 million 
low-income women of childbearing 
age ( WCBA), and this benefit is 
required to cover family planning 
FIGURE: Variation in Medicaid Postpartum LARC Insertion Coverage by State2,4 Policies also 
reviewed from individual state medicaid agency websites 
Device Insertion 
Part of Global Payment Separate Payment 
Part of Global Payment Part of Global Payment 
Separate Payment Separate Payment 
Separate Payment Part of Global Payment 
No Data Collected 
Postpartum LARC Coverage by State in Medicaid: 
Implications for Policy Improvement 
services without restrictive prior population and presents an enormous This research project evaluated the 
authorizations or cost-sharing.2, 4 opportunity for policy improvement. language that State Medicaid Agencies 
In non-Medicaid expansion states, Barriers to postpartum LARC used in describing their LARC poli-
m a ny WC BA on l y q u a l i f y  for  insertion exist at the state, health cies and postpartum LARC access 
Medicaid after becoming pregnant plan, provider and patient levels. The in particular in order to evaluate the 
and subsequently lose this coverage devices are expensive to stock and variation that exists across states. 
60 days after delivery. As such, women often poorly reimbursed by insurance The biggest variation in language 
who would like to start a LARC carriers. The Center for Medicaid regarded if the insertion procedure 
method would benefit from that Services (CMS) has provided guidance and the device itself were reimbursed 
method being available to them on postpartum LARC insertion rec- separate from the global maternity 
in the hospital after delivery and ommending that it be unbundled from payment as recommended by CMS. 
prior to discharge. This is called the global maternity payment, but The results are highlighted in the map 
postpartum LARC insertion, which each state has the autonomy to make created in Figure 1.2,4 The majority 
is a safe and highly efective method its own policies. Coverage policies also of states do reimburse for the LARC 
of contraception recommended by the depend on factors such as state distri- device or insertion outside of the 
American College of Obstetrics and bution of Medicaid through Managed global payment. However, little cor-
Gynecology.1 Despite the perceived Care of a Fee for Service Model or state relation could be found among state 
benefts of this insertion method, it expansion of Medicaid through the 
is under-utilized among the Medicaid Afordable Care Act. Continued on p. 24 
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Continued from p. 23 racism. Many of these issues still exist REFERENCES: 
political preference, demographics, or 
Medicaid distribution method. 
A l iterat ure rev iew revea led 
evidence from two states demon-
strating that after an unbundling 
policy change was implemented, more 
patients did receive LARC devices in 
today creating distrust of LARC in 
these communities.1 The goal of any 
policy would be to create an environ-
ment where women can choose their 
preferred method of family planning, 
while recognizing that unique barriers 
to LARC also need to be addressed. 
In conclusion, this research is only a 
When thinking about reproductive health policy, it is equally impor-
tant to acknowledge the historical context where black and poor 
women are frequently victims of reproductive coercion, forced ster-
ilization, and racism. Many of these issues still exist today creating 
distrust of LARC in these communities.1 
the immediate postpartum period.3,5 
The policy review also highlighted 
unique innovations to payment bar-
riers. For example, the state of Texas 
contracts with specialty pharmacies 
that bill Medicaid directly and ship 
LARC devices to providers to avoid 
high upfront costs.2 
When thinking about reproduc-
tive health policy, it is equally impor-
tant to acknowledge the historical 
context where black and poor women 
are frequently victims of reproductive 
coercion, forced sterilization, and 
small piece of the puzzle in terms of 
improving reproductive equity for 
all women. More research needs to 
be done to better understand what 
policy innovations will improve access 
to LARC among WCBA receiving 
Medicaid while preserving reproduc-
tive equity. In the short-term how-
ever, unbundling LARC device and 
insertion from the global maternity 
payment may be an easy frst step. 
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diate Postpartum Long-Acting Revers-
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ment of Health and Human Services Cen-
ters for Medicare and Medicaid Services, 
2016. (Accessed Oct. 4, 2019 at w w w. 
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downloads/cib040816.pdf ) 
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Group Relative MIPS PI PI POMP Query 
Size Percentile Non participation Incentive Incentive ($) 
(Percentage Score) ($) ($) 
Ind ividual 25th to 50th (37%) (580) 95 15 
(1) 
75th (85%) 400 1,800 230 
Small 25'h (0%) (37,000) NIA NIA 
(2-15) 
50th (37%) (4,100) 670 80 
75th (85%) 2,800 13,000 1,600 
Medium 25th (37%) (24,000) 4,000 500 (16-99) 
50th and up (85%) 17,000 75,000 9,700 
Large (100+) 25th and up (85%) 40,000 180,000 23,000 
Very Large 25th and up (85%) 200,000 890,000 120,000 (500+) 
Intended or Unintended Consequences of Medicare’s 
Merit Based Incentive Payment System (MIPS): 
Consolidation as a Requisite for Success 
David M. 
Kauffman, MSII 
ADVISORS: Brian 
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William Borden, 
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T he  u nce r t a i nt y  s u r r o u nd i n g  
Medicare Quality Payment Programs 
(QPP) such as the Merit Based 
Incentive Payment System (MIPS) 
has forced many organizations to 
strategize on how to achieve success 
under value-based payment systems. 
Originally promised larger payment 
incentives than received, many pro-
vider groups are questioning the efec-
tiveness of MIPS in achieving stated 
policy goals. At present, the MIPS 
score measures a provider organiza-
tion’s performance in four key areas: 
quality, cost, promoting interoper-
ability (PI), and improvement activi-
ties.1 The subsequent score received 
forms the basis for a negative, neutral, 
or positive Medicare Part B payment 
adjustment as shown in Figure. With 
the goal of investigating these trends 
and their implications for public 
policy moving forward, a financial 
model was created to predict the 
extent of PI participation for organi-
zations of varying sizes. This model 
specifcally analyzed the feasibility of 
PI measures because they are among 
the most capital-intensive measures 
and thus most useful in elucidating 
group decision-making. Ultimately, 
we sought to determine whether 
TABLE: Financial Incentives by Group Size and Percentile Performance. This 
table summarizes the incentives and fnancial penalties for varying levels of compliance 
with MIPS measures as determined by the fnancial model PI Nonparticipation is the 
Medicare payment adjustment received if the group decides to report a zero for PI 
measures to CMS  PI Incentive is the Medicare revenue gain if the group participates in 
PI to the percentage score of their respective percentile of overall MIPS performance  
The PDMP Query incentive is the revenue gain if the group decides to pursue the 5 
bonus points by searching a state PDMP database before prescribing an opioid  
Centers for Medicare and Medicaid 
Services CMS incentives were likely 
to be efective in achieving their goals 
and the ramifcations of the incen-
tives on the United States health care 
system as it transitions to value-based 
care. 
Solo, small, medium, large, and 
very large practices were modeled 
using available data and final rules 
published by the US Department of 
Health and Human Services (HHS).1 
MIPS payment adjustment projec-
tions were extrapolated for the range 
of possible MIPS scores as shown in 
Figure. The approximation of group 
MIPS performance under varying 
conditions was performed using 
quartile MIPS performance data 
generated from a sample distribution 
of approximate MIPS scores.2 
The resulting fnancial incentives 
for MIPS participation are shown 
in Table. MIPS incentivizes perfor-
mance proportionally, and as a result, 
the scale of operations is critical to 
the fnancial viability of compliance. 
Larger groups have a greater capacity 
to implement operational changes 
and make capital investments due to 
their fnancial leverage and advanced 
organizational structure. Also, larger 
groups likely have dedicated clinical 
leaders, more sophisticated electronic 
health record support, and contracts 
with experienced consultants to 
ensure maximal compliance with 
MIPS objectives. Small groups may 
not have the capital nor dedicated 
administrators to comply fully with 
Continued on p. 26 
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MIPS objectives, placing them at a 
disadvantage. Rather than invest in 
technological solutions to advance 
their health care practice, smaller 
organizations are more likely to 
maintain fnancial viability through 
non-compliance. 
Our analysis demonstrates that 
current MIPS policy creates a “reverse 
Robin Hood” efect whereby larger 
groups gain additional Medicare 
revenue on the backs of lower per-
forming, smaller groups. These larger 
groups inevitably absorb smaller 
groups that cannot survive under 
these conditions, making MIPS 
policy an efective force of consolida-
tion in the health care marketplace. It 
is conceivable that a long run goal of 
MIPS was to encourage consolidation 
so entities would be more responsive 
to policy changes in the future. In this 
way, MIPS may lead to an increase 
in overall health care quality in the 
U.S. health care system through the 
adoption of CMS value-based mea-
sures. Another goal may have been 
to encourage the creation of large 
entities capable of assuming fnancial 
risk in order to lower total Medicare 
expenditures. While the QPP value-
based payment system is still in its 
infancy in the United States, current 
FIGURE: Projected Payment Adjustments by MIPS Score for PY2019 [1]. CMS 
projections for the base incentive (1 11%) and exceptional performance bonus (3 58%) 
were distributed among the range of MIPS scores possible in the model to predict 
Medicare Part B incentive payments as a function of MIPS score received  
policy may also be incentivizing a pro-
vider market with less competition. 
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FIGURE 1: Surveys were queued based on the designed branching logic In this 
instance, H&N35 would be queued upon completion of QLQ30 and upon selection of 
“Subsequent Follow-Up QoL Head and Neck Cancer” (initial selection 6) by the team 
member
Radiation oncology (RadOnc) pro-
viders regularly incorporate quality 
of life (QoL) assessments into their 
practice to assess treatment toxicities 
and late efects of therapy. However, 
routine QoL assessments may burden 
patients and providers and disrupt 
clinical workflow.1 Electronic QoL 
assessment systems mitigate obstacles 
to collecting and analyzing patient 
data, such as poor handling of paper 
forms, transcription errors, and lack 
of validation checks.2 Electronic col-
lection systems provide an efficient 
and convenient means to the same 
end. To maximize efectiveness, these 
platforms must be implemented in a 
logical manner and emphasize protec-
tion of patient information. In this 
abstract, we outline our method for 
designing and implementing a web-
based QoL questionnaire and reposi-
tory in our RadOnc clinic. 
Our institution provides Research 
Electronic Data Capture (REDCap) 
to easily build online surveys and 
databases.3 REDCap is a noncommer-
cial, secure, and HIPAA-compliant 
web-based platform. This fast, fexible 
program can be used to export data to 
common data analysis packages and 
create custom ad hoc reports. 
O u r i nstit ution uti l izes the 
EORTC Quality of Life Group’s 
core questionnaire, the EORTC 
QLQ-C30 (QLQ30), and site-specifc 
modules to assess QoL of patients who 
received treatment for head and neck 
cancer (HNC), endometrial cancer, 
and cervical cancer. The EORTC 
QLQ-H&N35 (H&N35) is a widely 
used tool to measure QoL in HNC 
patients and has been validated in 
large-scale studies.4,5 We recreated a 
version of both the QLQ30 and the 
H&N35 in REDCap. 
The project was designed using 
longitudinal data collection. Due 
to variations in type and frequency 
of patient encounters, we define 
events by patients’ unique medical 
record numbers (MRN) and type of 
encounter. Combined with the assess-
ment date, we can analyze patient 
encounters over time. 
A team member initiates patient 
encounters by accessing REDCap, 
providing the patient’s MRN, and 
selecting the visit type. To access 
the H&N35, team members indicate 
that they are preparing a subsequent 
follow-up visit for an HNC patient. 
The project is designed with 
branching logic to queue a valida-
tion survey. We included this step 
to authenticate the response collec-
tion and to familiarize patients with 
the platform. Upon completion, the 
patient will be presented with the 
QLQ30 and then the H&N35. 
The project was designed to reduce 
patient decision-making and efort. 
Along with branching logic (Figure 
1), survey sections are displayed as 
matrices of felds and separated over 
different web pages when answer 
choices or response prompts change 
(Figure 2). This design was imple-
mented to limit patient confusion 
and promote data quality. Data vali-
dation techniques are also employed 
to ensure appropriate completion of 
each survey. 
After checking in at our clinic, a 
team member escorts the patient to 
an examination room, accesses the 
project in REDCap, enters initial 
patient information, and selects the 
visit type. Next, the team member 
assesses the completion of the initial 
validation survey and the frst ques-
tionnaire is selected and opened. The 
patient uses a laptop computer to 
complete the QoL surveys queued in 
the web-browser. 
Development of a simple and 
effective web-based platform for 
survey administration presents many 
challenges. The REDCap program 
facilitated this objective by enabling 
Continued on p. 28 
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efcient administration of web-based 
surveys. The QLQ30 and H&N35 
were foundational starting points 
upon which to expand our platform 
and assess other treatment sites. 
Given the simplicity of the REDCap 
platform, we have successfully admin-
istered surveys on tablet computers 
and aim to expand their utility. 
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Interpersonal communication has 
been drastically altered due to inno-
vations in technology.1 Emojis are 
currently an undeniable part of the 
world’s communication language 
and are utilized by 92% of the online 
population.2 They represent emo-
tional and personality nuances which 
would be present in face-to-face com-
munication.3 We sought to determine 
1 
6 
FIGURE: Ten different emoji faces  
whether emojis may be a tool that can 
efectively and efciently evaluate a 
patient’s mood in a busy emergency 
department (ED) setting. 
This was a prospective study 
performed at the ED of an urban 
academic center. Patients 18 years of 
2 3 4 5 
7 8 9 10 
age or above with lower acuity level 
at arrival (an Emergency Severity 
Index (ESI) between 3 and 5) were 
prospectively enrolled. Upon arrival 
to the ED, a screen with 10 dif-
ferent emoji faces ranging from one 
(extremely satisfied, smiling face) 
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to 10 (extremely dissatisfed, angry, 
red face) was given to each patient 
(Figure). Every 30 minutes after their 
arrival, patients were asked to identify 
their emotional state by selecting one 
mood-determining emoji. The change 
in emojis throughout the patient’s 
visit was recorded. The patient’s age 
and length of stay (LOS) were exam-
ined to assess the effect that these 
variables may have had on the patient’s 
frst and last selected emoji, and the 
change between the two. The analysis 
included time series, Spearman cor-
relation, multiple linear regression, 
categorical, nonparametric statistics 
and McNemar-Bowker Test of sym-
metry for paired emoji data. 
The study included 348 patients 
with valid emoji data. On the emoji 
scale, the mean emoji upon arrival 
to the ED and upon discharge were 
5.8 and 5.3 respectively (P=0.0004; 
Wilcoxon signed rank test), showing 
significant improvement in patient 
mood. When the patients frst arrived 
at the ED, 7% and 9% of the patients 
selected emoji #1 and emoji #10, 
respectively. Upon discharge, 10% 
and 9% of the patients selected emoji 
#1 and emoji #10, respectively. About 
32% of the patients did not change 
their emoji during their ED visit. 
About 30% exhibited improvements 
in their mood and a few displayed 
worsening mood (25%). The length 
of stay in the ED was not correlated 
to the change in emoji (P=0.11). The 
patient’s age also did not have an efect 
on the change in emoji (P=0.64). The 
Characteristics No. (%), Average 
Admission to ED 
First mood-determining emoji 5 8+2 7 
Emoji #1 selected 26 (7 4) 
Emoji #10 selected 30 (8 6) 
Mood-determining emoji for males 5 4+2 6 
Mood-determining emoji for females 6 2+2 6 
Discharge from ED 
Last mood-determining emoji 5 3+2 8 
Emoji #1 selected 36 (10 3) 
Emoji #10 selected 32 (9 2) 
Changes in Mood 
No change in mood 112 (32 2) 
Improved mood 104 (29 9) 
Worsened mood 88 (25 3) 
TABLE: Patient mood in the ED from admission to discharge  
mean emoji at admission for male 
patients was signifcantly lower than 
those for female patients (5.4+2.6 
vs. 6.2+2.6; P=0.006) and males dis-
played a slightly higher mood change 
(slope=0.52; P=0.065; Table). 
It is difcult for healthcare pro-
viders to ascertain a patient’s emo-
tional state to better assess how they 
are feeling about their medical issue 
or ED experience. Identifying tools 
that can improve this more nuanced 
but important aspect of emergency 
care could be useful. Our study has 
illustrated that emojis can be a useful 
tool in tracking a patient’s mood 
during the ED visit. Patients are very 
familiar and comfortable with emojis, 
so their use requires little explanation. 
Emoji assessments are very quick and 
simple to perform and have the poten-
tial to impact overall management in 
the ED. 
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Children with medical complexity 
(CMC) are children whose health 
care status encompasses four main 
areas: chronic, severe health condi-
tions; substantial health service needs; 
functional limitations, which are 
often severe; and high health resource 
utilization. Examples of children with 
medical complexities include, but 
are not limited to, those with con-
genital heart disease, cerebral palsy, 
spina bifda, sickle cell disease, and 
HIV/AIDS.1 These patients require 
individualized care, often involving 
round-the-clock caretakers who 
ensure adherence to multiple medi-
cations, address specifc dietary and 
feeding needs, and understand how 
to use medical technology associated 
with each patient’s condition. Such a 
high level of care may place a larger 
burden on parents of CMC than is 
feasible. Under these circumstances, 
medical foster care services provide 
additional support for families with 
medically complex children.2 
Second Family is a non-profit 
organization with medical homes 
throughout Maryland that house 
many of these CMC in the medical 
foster care system. Once patients 
enter Second Family, they receive 
pr i m a r y ca re ser v ices t h roug h 
C h i ld r e n’s  Na t ion a l  Ho s pit a l  
(Children’s National). However, in 
establishing this transfer of care, 
patients and their Second Family 
caretakers often arrive at appoint-
ments without adequate knowledge 
of patients’ medical and social back-
ground and needs. These information 
gaps create significant challenges 
for clinical providers when making 
medical decisions. In order to reduce 
these gaps, improve each provider’s 
care for Second Family patients, and 
foster collaboration between Second 
Family and Children’s National, we 
created a checklist for Second Family 
caretakers to use to prepare for each 
patient’s appointments. 
We approached this 
through a literature review on 
the needs of CMC, consultations 
with Complex Care pediatricians, 
and observation of patient-
provider and caretaker-provider 
interactions during Complex 
Care visits at the Child Health 
Center and Adolescent Health 
Center. 
➤ 3) Study: We collected feedback 
on the checklist through focus 
groups of stakeholders (parents 
and caretakers of Second Family 
patients, the Pediatric Medical 
Specialist at Second Family, 
Complex Care Team social 
workers, case managers, nurses, 
and physicians). 
➤ 4) Act: We revised the checklist 
until we reached a fnal product. 
project using the “Plan- We approached this project using the “Plan-Do-Study-Act”(PDSA) 
cycle, a quality improve-
Do-Study-Act” (PDSA) cycle, a quality improve-ment tool created as 
part of the Institute 
ment tool created as part of the Institute for for Healthcare’s Model 
for Improvement. This 
cycle involves creating a Healthcare’s Model for Improvement. 
plan or initiative and col-
lecting the necessary data (plan), testing 
the plan or initiative (do), studying the 
testing results (study), and then refning 
the initial plan accordingly (act). Our 
project was designed as follows: 
➤ 1) Plan: To develop a standardized 
clinical checklist for complex 
care visits with Second Family 
patients at Children’s National. 
➤ 2) Do: We identifed important 
elements for the checklist 
Through implementation of this 
checklist, we not only aim to improve 
the Complex Care Team’s ability to 
care for Second Family patients, but 
also intend to educate Second Family 
caretakers regarding what informa-
tion they need bring to healthcare 
visits. We hope that our checklist will 
serve as a tool or template for other 
measures of standardizing care among 
children with medical complexities 
and their caretakers, families, and 
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providers. This tool may also be 
expanded and externally validated 
via use in other populations, such 
as Second Family patients visiting 
Children’s National’s Emergency 
Department, foster families with 
CMC not in a group medical home, 
adults with medical complexities, and 
general primary care visits. 
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The advent of telehealth services 
has been a critical turning point in 
healthcare delivery that has been 
expanding access, reducing costs, and 
improving health outcomes. Under 
the current fee-for-service Medicare 
payment model, telehealth coverage 
is limited to rural areas, which are 
defned as health professional shortage 
areas, to reduce over uti l ization 
and keep costs down.1 A recent 
study showed that telemedicine 
ut i l i z at ion  i n  r u r a l  Me d ic a r e 
populations, particularly for mental 
health, complemented healthcare 
management, but did not increase 
utilization.2 Moreover, factors such as 
geographical restrictions on telehealth 
coverage may be impeding the growth 
of telehealth. Others argue that 
expanding telehealth service coverage 
may increase utilization and drive up 
healthcare costs.1,3 While these are 
valid points, the impact of telehealth 
on overall healthcare utilization 
patterns is not well understood in the 
Medicare population. The University 
of California, San Francisco (UCSF) 
is a quaternary care center that is 
uniquely positioned in that it has 
consistently offered telehea lth 
to all patients regardless of payer 
s t a t u s  .  T h u s ,  
m a n y  M e d i c a r e  
patients who utilize 
UCSF’s telehealth 
a r e  n ot  co v e r e d  
f o r  t e l e h e a l t h  
s e r v ice s .  I n  t he  
current study, we 
determined if there 
was a relationship 
between telehealth 
u t i l i z a t i o n  a n d  
o v e r a l l  h o s p it a l  
u t i l i z a t i o n  i n  
t h e  M e d i c a r e  
Our fndings indicate that telehealth utilization is 
associated with an overall decrease of ED utiliza-
tion in the Medicare population. However, the 
relationship between telehealth use and other 
utilization patterns (e.g. clinic visits, emails) is 
likely confounded by variables such as the under-
lying disease and technological literacy. 
p o p u l a t i o n  a t  U C S F.  S u b s e t  
analyses on Medicare patients was 
performed using data from two of the 
highest utilizing telehealth clinics: 
Symptom Management Clinic and 
Endocrinology Clinic. To determine 
if telehealth services among Medicare 
patients was associated with decreased 
hospital utilization, we used ED 
visits as the primary outcome and 
outpatient visits as well as patient 
portal interactions as covariates. 
Results show that there was a 
significantly smaller percentage of 
telehealth patients that utilized the 
ED versus non-telehealth patients in 
both clinics (40% vs. 48%, respectively, 
for Symptom Management Clinic 
and 11% vs. 24%, respectively, for 
Endocrinology Clinic). We used a 
Poisson regression to model our data 
and it showed that the incidence 
rate of ED visits among telehealth 
users (IRR, 95% CI) is signifcantly 
less than that among non-telehealth 
Continued on p. 32 
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users in the Symptom Management 
Clinic and Endocrinology Clinic 
(0.78 and 0.52, respectively). There 
was heterogeneity in the relationship 
between telehealth visits and ofce 
visit patterns, with the Symptom 
Management Clinic demonstrating 
equivalent office visit utilization 
between telehealth and non-telehealth 
users while the Endocrinology Clinic 
showed a slightly greater percentage of 
telehealth users who had ofce visits 
compared to non-telehealth users 
(99.1% vs. 97.5%, respectively). Lastly, 
telehealth users had significantly 
more patient portal interactions 
on average when compared to non-
telehealth users in both clinics. Our 
findings indicate that telehealth 
utilization is associated with an 
overall decrease of ED utilization in 
the Medicare population. However, 
the relationship between telehealth 
use and other utilization patterns 
(e.g. clinic visits, emails) is likely 
confounded by variables such as the 
underlying disease and technological 
literacy. Future studies are needed 
to better understand the impact of 
telehealth on overall care utilization. 
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Low-income countries are facing 
the double burden of communicable 
diseases and rising prevalence of 
noncommunicable diseases (NCDs).1 
Traditionally, community health 
workers (CH Ws) have played a 
signifcant role in the prevention and 
control of communicable diseases 
such as malaria, tuberculosis, and 
HIV.2 However, the involvement 
of CHWs in NCD prevention and 
control has not been fully explored, 
especially in many Low- and Middle-
Income Countries (LMICs) including 
Uganda.3 This direct participant 
observational study examines how 
well CHWs receive, comprehend, and 
engage with Omni Med’s hypertension 
quarterly training. Omni Med is a 
non-profit organization working 
to reduce global health inequity 
in developing countries through 
innovative programs focused on 
communit y education, bui lding 
sustainable solutions, and health 
volunteerism. CHW demographics 
and contacts were obtained from 
Omni Med. Starting August 2019, 
CHWs were invited for a day-long 
training targeting hypertension risk 
factors such as the effects of high-
stress levels, alcoholism, and excess 
carbohydrate consumption. After 
each training, CHWs were assessed 
on their understanding of the topics 
and given the opportunity to ask 
questions and brainstorm solutions. 
Their responses were collated and 
used to cater future sessions to their 
goals, concerns, and knowledge base. 
Since the implementation of the 
training, 269 CH Ws have been 
trained. Dialogues and brainstorming 
sessions with CHWs demonstrated 
that they grasped the effects of 
diet, alcohol, and stress on blood 
pressure a nd agreed that these 
three rampant risk factors existed 
in their villages given the state of 
widespread poverty.4 From these 
dialogues and brainstorming sessions 
emerged three key themes which 
afrmed the CHWs comprehension 
and engagement with the training 
material. First, CHWs provided 
further points of discussion on the 
causes of hypertension and frequently 
brought up other chronic NCDs like 
diabetes and their relationship to 
hypertension. Second, they provided 
insight into some of the physical 
and mental health misconceptions 
that exist within their communities. 
For example, some CHWs seemed 
to think that certain home-brewed 
alcohol is “good for you,” so we have 
tried to clarify this by dispelling 
the misconception and educating 
them on the health consequences 
of all kinds of alcohol. Third, they 
have demonstrated a willingness 
to spa rk ch a n ge for i mproved 
health outcomes through education 
and health promotion measures. 
Relatedly, CHWs suggested that 
male CHWs should talk with male 
community members and females 
CH Ws w ith fema le communit y 
members to promote a more trusting 
environment of mutual understanding 
with sensitive topics. After the 
training, CHWs exhibited greater 
confdence in their understanding of 
hypertension and desire to play key 
roles in its prevention and control 
within their communities. Future 
training for CHWs should consider 
providing a broader package of 
information beyond hypertension to 
cover more NCDs. 
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Preimplantation genetic testing 
(PGT) is a screening modality used in 
conjunction with in-vitro fertilization 
(IVF). For parents concerned about 
hav i ng a ch i ld w ith sick le cel l  
disease (SCD), PGT is an option 
to have progeny negative for the SS 
phenotype. Parents who already have 
a child with sickle cell disease (SCD) 
may also consider PGT as an option to 
have a sibling who is an HLA subtype 
match. Parents’ views of this pre-
conceptive diagnostic screening are 
not well known1 and little work has 
been done in educating parents about 
this process2,3. This study sought 
to describe parents’ opinions on 
PGT after a clinic-based educational 
intervention. 
Methods 
A five-page educational handbook 
was created on PGT for SCD. At 
the Children’s National Hospital 
(Children’s National) Hematology-
Oncology Clinic, parents of children 
with SCD were encouraged to read 
this handbook in the waiting room 
and ask their provider questions about 
the material during their clinic visit. 
After this visit, parents were then 
asked to complete a 24-question 
anonymous survey via REDCap (see 
figure 1 below). An IRB waiver of 
consent was granted as no personal 
FIGURE: Page one of PGT survey completed by parent participants  
health information was collected. 
Non-biological parents and other 
guardians were excluded. Categorical 
data from the survey was analyzed 
with the chi-square or Fisher exact 
test (p<0.05=signifcant). 
Results 
B e t w e e n  M a y  a n d  Ju l y  2 019 ,  
83 biological parents of children 
with SCD were enrolled into the 
study. Sixty-seven (81%) of these 
parents, including 52 mothers and 
15 fathers with a median age of 34 
years, completed the questionnaire. 
While 53 (79%) indicated that they 
had previously heard of bone marrow 
transplant for SCD before the date 
of the questionnaire, only 16 (24%) 
indicated that they had also heard of 
PGT for SCD (p<.0001). When asked 
about their opinion of informing 
the parents of SCD children about 
PGT, 45 (67%) stated that “knowing 
about PGT was ‘very important’,” 20 
(30%) responded PGT education was 
“important,” one responded (2%) “a 
little important,” and one (2%) “not 
important.” The majority (69%) of 
parents indicated that education on 
this topic should occur “at the very 
first hematology clinic visit.” Nine 
(13%) responded that they would pay 
retail price (~$20,0000) for PGT 
and 65 (97%) answered that they 
think PGT should be covered by 
health insurance. Among parents 
who indicated that they might want 
to have more children (n=32), 29 
(91%) answered that they would be 
interested in using PGT if covered 
by insurance. 
Conclusion 
Most parents of children with SCD 
seen in the Children’s Nationa l 
hematology-oncology clinic do not 
know about PGT, but when educated 
about this option, they view this 
knowledge as important. Routine 
follow-up appointments in early 
childhood may be an opportune 
time for educating patients on 
PGT. Though the current cost of 
PGT remains a major barrier, this 
preconceptive diagnostic screening 
method may prove to be a major 
inf luence in reducing the number 
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of pediatric patients with SCD, and 
providers should be sure educate 
parents on PGT to help ensure access 
to this option. 
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Assessment of Patterns in Surgical Backlog Within 
Ethiopian Public Hospitals as a Primary Step in 
Quality Improvement of Safe Surgeries 
to safe, afordable surgical and anes- study the details of surgical backlog of nine surgical departments; ENT, 
thesia care when needed.1 In Eastern among six Ethiopian public hospitals General, Neurosurgery, OB-GYN, 
sub-Saharan Africa, over an additional in the Amhara region. O pht h a l molog y,  O r t hop ed ics ,  
17 million surgical procedures are Standardized surveys were sent Pediatrics, Plastics, and Urology. In 
needed annually to prevent morbidity out to the surgical department of addition to the survey, first person 
and mortality.1 The Commission set six Ethiopian public hospitals in interviews with the chair of various 
out universal targets to achieve the the Amhara region: Debre Markos surgical departments were conducted 
proposed goals; one of which is for Referral Hospital, Dessie Referral at Gondar Hospital. 
100% of countries to track surgical Hospital, Debre Birhan Referral When looking broadly at all cen-
volume and preoperative mortality Hospita l, Debre Tabor Genera l ters, there were a total of 4207 cases 
rate (POMR).1 The Ethiopian Federal Ho s p it a l ,  G o n d a r  Un i v e r s it y  of backlog. According to Figure 1, 
Ministry of Health’s Health Service Comprehensive Specialized Hospital, the departments with the greatest 
Qua lit y Directorate recognizes and Feleghiwot Referral Hospital. backlog were General with 2044 
this importance by listing it under Among the questions asked was the cases accounting for 49% of the 
its National Health Care Quality total number of patients on the waiting 
Strategy.2 This investigation looks to list for elective surgery under one 
Continued on p. 36 
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The Lancet Commission on Global 
Surger y established the goal for 
nations to achieve universal access 
FIGURE 1: Summary of Surgical Backlog Assessed by Specialties Among Six 
Ethiopian Public Hospitals 
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Figure 2: Summary of Surgical Backlog Assessed by 
Diagnoses at Gondar Hospital 
Continued from p. 35 
total, Orthopedics with 652 cases at 
15%, and ENT with 496 cases at 12%. 
Each hospital has its own profle of 
needs, ref lecting the complexities 
faced by regional health bureaus. As 
a case sample, in depth analysis was 
conducted at Gondar Hospital which 
recorded 1,762 cases. The pattern of 
backlog varied compared to that of 
the overall fndings, with 45% of cases 
within General Surgery, while 30% 
were within ENT. Figure 2 highlights 
how the diagnoses associated with 
the highest backlog are tonsillitis at 
44%, and goiters at 30% of all hospital 
surgical cases. First person interviews 
conducted among the various surgical 
department heads highlighted that 
the main causes of backlog are due to 
either space or equipment limitations; 
the quality and quantity of human 
resources are adequate. 
One limitation of the study is 
the var ying methodologies used 
to monitor backlogs. For example, 
Ophthalmology at Gondar’s Hospital 
maintains its own records in hard 
copy, while records from other depart-
ments are maintained on a centralized 
electronic system. Another limitation 
is recognizing that low backlog does 
not necessarily indicate low burden. 
At Gondar Hospital, there is lack of 
FIGURE 2: Summary of Surgical Backlog Assessed by Diagnoses at Gondar Hospital 
OB-GYN backlog burden because of 
public health campaigns to champion 
maternal and child health outcomes. 
Simultaneously, there is also minimal 
backlog within Neurosurgery because 
cases that the hospital is unable 
to support are referred elsewhere, 
highlighting that the burden may be 
shifted to another site. In conclusion, 
assessing the tremendous baseline 
of surgical backlog is the first step 
to tracking the hospitals’ surgical 
volume and POMR. Individual hos-
pitals must be investigated in depth to 
assess their specifc needs. It is recom-
mended that future steps be taken to 
minimize the backlog and determine 
evidence based methods to prevent 
future occurrences. The success and 
limitations of these future steps can 
be used to inform strategies at other 
Ethiopian public hospitals. 
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Exam category Pre-course mean Pre-course Post-course Post-course WSRp-value 
± SEM(¾) range(%) mean ± SEM range(%) 
(%) 
Multiple choice 95.24 ± 2.32 86.1 1-100.00 99.21 ± 0.79 94.44-100.00 0.10 
Oral translation: 80.00 ± 5.85 60.00-100.00 93.57 ± 3.22 80.00-100 .00 0.08 
English to 
Spanish 
Oral translation: 81.43 ± 3.88 70.00-95.00 95.71 ± 2.76 80.00-100.00 0.03* 
Spanish to 
English 
SEM: Standard error of the mean 
WSR: Wilcoxon signed-rank test 
• indicates statistical significance 
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There are 58.9 million Hispanics 
in the United States.1 This number 
makes up 18.1% of the nation’s popu-
lation and is expected to increase 
to 24.5% by 2050.1 Nearly 40% of 
Hispanic patients are categorized as 
having limited profciency in English.2 
With the aim of training future 
health care providers with adequate 
Spanish profciency, many health sci-
ences institutions have implemented 
medical Spanish courses. Although 
interactive courses have shown ef-
cacy in teaching field-related ter-
minology, there are still signifcant 
barriers to implementing a medical 
Spanish curriculum.2,3 According to a 
national survey of medical schools in 
the United States, lack of time is the 
most frequently reported obstacle.2 
Role-play may ofer a time-efcient 
manner for students to learn Spanish 
and reduce this barrier. In our study, 
we investigated the potential beneft 
of role-play in a medical Spanish 
course. 
Methods: 
Upon receiving approva l by the 
Instit utiona l Rev iew Boa rd, 19 
incoming second-year medical stu-
dents were recruited to participate. 
Based on their performances on a 
placement test composed of multiple 
TABLE: Comparison of pre-course and post-course examination scores in the 
intermediate group 
ex a m i n ation scores,  t here wa s 
improvement of scores in all catego-
ries (Table). In particular, we found 
statistically signifcant improvement 
in oral translation of phrases from 
Spanish to English (p-value= 0.03). 
a Spanish-spea king 
patient, an English- [W]e found statistically signifcant improve-
speaking provider, and 
an interpreter to prac- ment in oral translation of phrases from 
tice scenarios that one 
may encounter when Spanish to English (p-value= 0.03). 
providing health care. 
The scena rios con-
sisted of patients presenting to the 
emergency department, outpatient 
clinic, and inpatient hospital setting. 
At the end of the course, students 
took a post-course examination 
to determine if there had been an 
improvement in their Spanish lan-
guage profciency. Due to the non-
normal distribution of scores, statis-
tical analysis was performed using 
Wilcoxon signed-rank test. Statistical 
signifcance was determined using a 
p-value < 0.05. 
Results: 
Seven students, who were all members 
of the intermediate group, completed 
the course. Class attendance among 
this group was 77.40%. When com-
paring pre-course to post-course 
Conclusions: 
We investigated utilizing role-play 
as the central teaching method in a 
medical Spanish course. The cohort 
demonstrated statistically signifcant 
improvement in oral translation of 
phrases from Spanish to English, 
indicating an improvement in Spanish 
profciency. More importantly, this 
was accomplished through a minimal 
time requirement of one hour per 
week, as limited time poses a barrier 
to implementing a medical Spanish 
curriculum. Such fndings highlight 
the beneft of this teaching method-
ology and call for further evaluation 
in a larger sample size. 
Continued on p. 38 
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Variab le P-value 
Season 
All Year 0.1464 
Soring 0.3618 
Summer 0.2499 
Fa ll 0.1219 
Winter 0.2804 
Age Group 
0-10 <0.0001 • 
11-17 <0.000 1 • 
18-25 0.0480 
26-34 0.0784 
35 and up <0.0001 • 
VA Association 
VA Partner 0.0234 
VA Partner Type 0.0174 
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Adaptive sports are broadly defned 
as conventional sports that have been 
modifed to meet the needs of people 
with physical and/or intellectual dis-
ability. Recently, an emerging body 
of literature dedicated to individuals 
with disability has demonstrated 
that participation in adaptive sports 
is associated with certain benefits, 
including chronic disease prevention, 
increased muscle strength, improved 
sense of self esteem and self image, 
as well as better social integration.1,2 
Additional studies have even sug-
gested participation in adaptive 
sports makes a diference in attaining 
employment.3 Among those with dis-
ability, U.S. Military veterans are a 
particular group of interest in part due 
to the infux of veterans living with 
disability in the post-9/11 era. Data 
from the 2014 Census demonstrates 
that there are at least 3.8 million 
FIGURE 1: 
veterans living with service-related 
disability.4 Given the documented 
physical, psychosocial, and socioeco-
nomic benefts associated with adap-
tive sports, it is critical that we con-
tinue investigating means to increase 
participation rates among veterans 
with disability. Known barriers to 
participation include difcult access 
to transportation, limited informa-
tion about programs and their ofer-
ings, individual cost, and program 
funding.5 Many of these obstacles 
are cost-related. Despite the large 
number of adaptive sports programs 
in the United States, little is known 
about the organizations that provide 
adaptive services. To our knowledge, 
there are no studies that specifcally 
focus on the organizational factors 
U.S. Military veterans fnd desirable 
when considering getting involved in 
adaptive sports. 
Objective: 
The aim of this study was to capture 
the factors within adaptive sports 
organizations and their surrounding 
communities that impact U.S. mili-
tary veteran participation in adaptive 
sport activities. 
Design, Setting, and 
Participants: 
This study was approved by the 
Institutional Review Board at the 
George Washington Universit y, 
as well as the Milwaukee, VA. A 
9-question survey was created by 
the investigators of the study and 
distributed to 121 programs across the 
United States (Figure 1). Participating 
organizations were identifed if they 
were advertised in the resources sec-
tion under “Sports and Recreational 
Orga n i zations” on w w w.spor t-
sabilities.com/[STATENAME]. 
Additionally, surveys were sent to 
programs known to the authors, but 
not listed on the Sports Abilities 
website. Chi-Square Tests were used 
to explore possible factors, including 
program status, the total number of 
participants and veteran participants, 
participant age, sports ofered, sea-
sonality, and relationship with the 
VA, potentially affecting veteran 
participation in adaptive sports 
programs. Due to the high number 
of tests performed, to control the 
family-wise error, p-values were not 
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considered to be signifcant unless 
they were smaller than 0.005. 
Intervention: 
Prospective, cross-sectional nine-
question survey about the program’s 
demographics. 
Main Outcomes and 
Measures: 
Demographic data. 
Results: 
In total, 85 programs responded to 
our survey, yielding a response rate 
of 70%. Age of participants within 
an organization was significantly 
associated with percentage of veteran 
participation. Contact level, season-
ality, and VA partnership were not 
associated with percentage of veteran 
participation (Figure 2). No individual 
sport was signifcantly associated with 
percentage of veteran participation, 
though fy-fshing approached statis-
tical signifcance (p = 0.007) 
Conclusions and 
Relevance: 
Older age among participants within 
an adaptive sports organization was 
associated with a higher percent of 
veteran participation, suggesting 
that the camaraderie developed with 
similar aged individuals is important 
to veterans when choosing adaptive 
sports programs. No sport was sig-
nifcantly associated with percent of 
veteran participation, illustrating that 
factors beyond the specifc activities 
ofered by a program impact veteran 
participation rates. 
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Cardiac rehabilitation (CR) programs 
employ a multipronged approach of 
exercise and lifestyle modifcations 
to reduce cardiometabolic risk fac-
tors, improve physical function, and 
improve quality of life for patients 
with a wide range of cardiac patholo-
gies. Prior research has demonstrated 
that cardiac rehabilitation can ben-
eft both men and women’s exercise 
capacity after sustaining a myocardial 
infarction (MI).1 However, women 
are consistently underrepresented 
in CR and are often referred to CR 
only when they present with greater 
cardiovascular risk than men.2 
The purpose of this systematic 
review is to investigate the diferences 
in functional capacity, measured 
by metabolic equivalents (METs), 
between men and women after an 
intensive cardiac rehabilitation pro-
gram for MI recovery. While several 
systematic reviews have compared 
compliance and referral rates between 
men and women to cardiac rehabili-
tation, none have assessed potential 
diferences in functional capacity or 
other health outcomes. 
Search strategies were developed 
using MeSH heading and free-text 
terms for four databases: PubMed, 
S C OP US ,  a nd  C I NA H L ,  a nd 
Cochrane. Article duplicates were 
FIGURE: Metabolic Equivalents (kcal/kg/hour) by Gender 
eliminated and the remaining titles 
and abstracts were screened. Papers 
were considered relevant if they 
compared outcomes in cardiac reha-
bilitation between men and women, 
if they were published in English and 
if they were classifed as a random-
ized or observational study. Data was 
collected using a standardized form, 
recording study type, the study popu-
lation, what, if any, cardiac rehabilita-
tion was implemented, the time points 
at which the outcomes were measured 
and the functional exercise outcome 
regarding MET improvements. 
A total of 9,986 records were iden-
tifed from the preliminary search and 
15 studies were ultimately included in 
the review. No eligible randomized 
controlled trial was identifed. All 15 
studies utilized in this review reported 
that both men and women benefit 
from cardiac rehabilitation, as dem-
onstrated by a statistically signifcant 
increase in peak METs in both gender 
groups after CR. Improvements in 
absolute METs during CR, reported 
by 13 studies, ranged from 0.9 to 2.6 
for women and 0.8 to 3.8 for men. 
Percent improvements in METs from 
baseline, reported by four studies, 
ranged from 6.1% to 35% in women 
and 10.6% to 45% in men. Six studies 
showed MET improvement with CR 
to be greater than that of women 
by a statistically signifcant margin. 
However, only one study showed the 
reverse, a greater MET improvement 
with CR for women than men, to 
be true in a statistically signifcant 
fashion. The remaining eight studies 
showed no statistically signifcant dif-
ferences between men and women in 
regards to change in METs with CR. 
Although all 15 studies demon-
strated that both men and women 
benefit from CR in terms of MET 
improvements, the majority of studies 
had more males than females as 
study subjects and thus in their CR 
programs. Given the proportional 
underrepresentation of women in 
these studies, however, it is difcult 
to speculate the existence of a true 
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difference in MET improvements 
and also the reasons for a such a dif-
ference. Further research is needed 
to solidify these diferences in peak 
MET improvement between the 
genders, if they are true representa-
tions of the study population, with 
increased numbers of female study 
subjects included. 
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FIGURE: (A) Differential abundance of bacterial metabolic pathways between 
exacerbation onset samples (left) and end of antibiotic treatment samples (right) (B) 
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and follow-up samples (right)  (C) Differential abundance of bacterial metabolic pathways 
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Introduction/Rationale 
Cystic Fibrosis (CF) is an autosomal 
recessive disease affecting more 
than 30,000 people in the United 
States. Pulmonar y exacerbations 
(PEx) are the most important cause 
of morbidity and ultimately mor-
tality in patients with CF.1 Despite 
many studies of bacterial taxonomy 
and microbial diversity in the CF 
airway, the microbiologic cause of 
PEx remains unknown. While early 
unbiased whole genome sequencing 
studies have yielded greater insights 
into species and strain specificity,2 
the role of bacterial functional path-
ways in CF PEx is understudied. We 
hypothesized that bacterial metabolic 
pathways would be associated with 
clinical state (PEx, end of antibiotic 
treatment, and follow-up). 
Methods 
Twenty seven persons less than 18 
years of age with cystic fbrosis, who 
were admitted to the hospital for a 
PEx, were recruited to participate 
in this prospective observational 
study. Sputum or orophar yngeal 
swabs were collected at hospital 
admission, at the end of the antibi-
otic treatment course, and again at 
the next follow up clinic appoint-
ment within three months. Bacterial 
DNA was extracted using QIAamp 
DNA Microbiome kit (Qiagen) and 
shotgun DNA sequencing was per-
formed using NextSeq (Illumina). 
Continued on p. 42 
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HUMAnN2 was used to evaluate 
bacterial pathway abundance and 
DESeq2 was then used to evaluate the 
diferential abundance of generalized 
bacterial metabolic pathways based 
on clinical state. 
Results 
Several pathways related to virulence, 
pathogenicity and bacterial metabo-
lites were upregulated in follow-up 
samples when compared to PEx onset 
or end of antibiotic treatment sam-
ples. Interestingly, we found several 
long chain fatty acid (LCFA) biosyn-
thesis pathways that were upregulated 
in follow-up samples (Figure). These 
include gondoate (log2 fold change 
1.59, p=0.012), oleate (log2 fold change 
1.746, p=0.048), palmitoleate (log2 
fold change 1.766, p=0.043), and path-
ways of fatty acid elongation (log2 
fold change 2.06, p=0.012). While 
short chain fatty acids (SCFAs) have 
been shown to reduce infammation, 
LCFA’s have previously been associ-
ated with increased lung infamma-
tion in asthma, another important 
airway disease. 
Conclusions 
While most current research on 
LCFAs and the lung pertain to fatty 
acids introduced through diet or in 
the lab, we hypothesize that LCFAs 
produced by lung pathogens in the CF 
airway can have a physiologic efect 
like gut derived bacterial SCFAs. 
Gut derived SCFA’s have been 
studied extensively as yielding a 
protective effect on inf lammation 
leading to protection in infammatory 
diseases across multiple organ systems 
and to be associated with infamma-
tory illnesses.3 In contrast, LCFAs 
introduced through diet and in the lab 
have been shown to induce bronchial 
cell proliferation, airway remodeling 
and airway smooth muscle contrac-
tion – all important factors in lung 
infammation and exacerbation.4,5 
As we found long chain fatty path-
ways to be upregulated in follow-up 
samples, LCFAs produced by bacteria 
in the CF lung should be studied fur-
ther for potential impact on future 
PEx. This may help us further char-
acterize the role of bacteria produced 
LCFA’s on the transition between 
clinical states. 
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Outcome 
EDVT unadjusted 
OR (95% CI) or 
unadjusted ln[β
(SE)] 
Unadjusted 
P 
EDVT 
adjusted 
OR (95% CI) 
or adjusted 
ln[β (SE)] 
Adjusted 
P 
Death 1 19 (0 97 - 1 47) 0 1033 
0 99 (0 75 – 
1 32) 
0 9863 
Vent Days 0 0332 (0 0375) 0 3752 
0 0760 
(0 0408) 
0 0627 
ICU Days -0 0072 (0 0393) 0 8539 
0 0468 
(0 0442) 
0 2901 
Hospital Days -0 0224 (0 0420) 0 5942 
0 0331 
(0 0485) 
0 4951 
Learning Objectives 
Mechanical ventilation is a lifesaving 
therapy however, it may pose a threat 
to patients if set inappropriately. Prior 
studies suggest that tidal volumes 
(TVs) based on ideal body weight 
(IBW) are associated with improved 
outcomes for intubated patients. We 
sought to determine whether TV set-
tings based on IBW correlated with 
clinically relevant patient outcomes 
for patients intubated in the emer-
gency department (ED). 
Methods 
We performed a retrospective review 
of electronic medical records from 
January 2016 to December 2018 for 
intubated patients in the ED. We col-
lected data including: patient demo-
graphics, height, weight, lab values, 
and ventilator settings in the ED. 
We calculated IBW for all patients to 
determine the tidal volume per kilo-
gram given in the ED. We stratifed 
TABLE: The Effect of Tidal Volume Settings in the ED on Patient Outcomes  
the TVs based on low (<8cc/kg ), 
intermediate (8-10cc/kg), and high 
(>10cc/kg). We assessed the impact 
of TV on the following outcomes: 
ventilator days, intensive care unit 
(ICU) days, hospital days, and death. 
Multivariable logistic and general 
linear models were assessed adjusting 
for baseline demographics, clinical 
variables, and illness severity to better 
elucidate the independent efect of 
tidal volume on outcomes of interest. 
Length of stay (LOS) outcomes were 
natural logarithm (ln) transformed to 
meet the assumptions of normality 
and linear regression. 
Results 
Two hundred seventeen patients had 
full data record for analysis. Average 
age was 59.7 ± 15.4 years old (mean 
± standard deviation). 90 (41.5%) 
patients were female and 127 (58.5%) 
were male. Median SOFA score was 8 
with interquartile range 6–11. Median 
LOS for days on ventilator, days in 
ICU, and days in hospital were 3, 5, 
and 8, respectively. 64 (29.5%) patients 
experienced mortality. Adjusted 
analysis detected no independently 
signifcant relationship between any 
of the IBW ED tidal volume per kg 
and mortality, ICU days, or hospital 
days (Table). 
Conclusions 
This data suggests that the TV size 
did not significantly affect patient 
outcomes. There was no association 
between low, intermediate or high 
TV and mortality, ventilator days or 
hospital days. 
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Emergency department (ED) visits 
for acute gout have increased by 
approximately 20% between 2006 
and 2014.1 Reducing the ED length of 
stay (LOS) can help reduce cost of care 
for gout patients and ED crowding.2 
We assessed the ED LOS and factors 
associated with it in patients with acute 
gout. A retrospective analysis was 
conducted and included the frst ED 
visit of adult patients with acute gout 
who presented to the 3 EDs afliated 
with Lifespan Health Systems, the 
largest healthcare provider in Rhode 
Island. The ED LOS was the time 
spent by patient in the ED until they 
were discharged. Patients presenting 
to the ED and subsequently admitted 
to the hospital were excluded given 
the diferential efect of system fac-
tors in these patients. Both patient 
factors, such as clinical presentation 
of gout, as well as systems factors were 
assessed. Univariate and multivari-
able analysis were completed. The 
univariate analysis demonstrated that 
patient factors such as older age (>65 
years), comorbidities (hypertension, 
congestive heart failure), and worse 
ED severity score were associated 
with being in the upper quartile of ED 
< 4.3 hours in ED 
(n = 265) 
> 4.3 hours in ED 
(n = 90) 
Patient factors 
Age < 65 185/265 (69 8%) 51/90 (56 7%) 
Male gender 213/264 (80 7%) 75/90 (83 3%) 
Comorbidities 
Diabetes 68/228 (29 8%) 29/76 (38 2%) 
Hyperlipidemia 132/228 (57 9%) 53/76 (69 7%) 
History of gout 160/228 (70 2%) 54/76 (71 1%) 
Hypertension* 162/228 (71 1%) 65/76 (85 5%) 
Coronary artery disease 49/228 (21 5%) 21/76 (27 6%) 
Heart failure* 32/228 (14 0%) 26/76 (34 2%) 
Chronic kidney disease 44/228 (19 3%) 21/76 (27 6%) 
Cerebrovascular disease 19/228 (8 3%) 4/76 (5 3%) 
Other infammatory arthritis 10/228 (4 4%) 3/76 (4 0%) 
Clinical presentation of gout 
Oligo/polyarticular gout 33/265 (12 4%) 13/90 (14 4%) 
Arthrocentesis* 21/265 (7 9%) 51/90 (56 7%) 
ED Severity Score* 
Score 2 and 3 
Score 4 and 5 
117/265 (44 1%) 
148/265 (55 8%) 
67/90 (74 4%) 
23/90 (25 6%) 
Systems factors 
Type of Hospital* 
Academic center 
Community center 
204/265 (77%) 
61/265 (23%) 
82/90 (91 1%) 
8/90 (8 9%) 
Time of Day 
Time of day (12 am – 8 am) 
Time of day (8 am – noon) 
Time of day (noon – midnight) 
52/265 (19 6%) 
124/265 (46 8%) 
89/265 (33 6%) 
20/90 (22 2%) 
51/90 (56 7%) 
19/90 (21 1%) 
Time of Year 
January to March 
April to June 
July to September 
October to December 
43/265 (16 2%) 
94/265 (35 5%) 
78/265 (29 4%) 
50/265 (18 9%) 
21/90 (23 3%) 
28/90 (31 1%) 
19/90 (21 1%) 
22/90 (24 2%) 
Weekend presentation 94/265 (35 5%) 24/90 (26 7%) 
*Represents statistically signifcant results (p <0 05) 
TABLE: Factors Associatedwith Increased ED Length of Stay in Gout Patients 
LOS in addition to being treated in greater than 65 years and a worse acuity 
an academic setting. A multivariable score continued to be associated with 
analysis showed that persons of age longer ED LOS. Overall, the study 
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demonstrated patients with acute gout 
spent a longer time in the ED than the 
national median of 120-150 minutes. 
Older age and a higher acuity score in 
addition to procedural delays led to 
longer length of stay in the ED. 
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Learning Objectives 
Given the high mortality rate in 
patients with cardiac arrest, previous 
research has sought to determine 
factors that distinguish patients 
who are likely to have return of 
spontaneous circulation (ROSC) 
from those in whom continued 
resuscitation is futile.1 Prior research 
utilizing multiple imaging modalities 
such as Ultrasound and CT scan 
has suggested an association of the 
presence of hepatic venous air with 
mortality.2 As point of care ultrasound 
(POCUS) is already becoming more 
frequently used in the context of 
resuscitation, we sought to evaluate 
if the presence of any hepatic air, 
parenchymal or venous, on POCUS 
had a similar mortality association. 
Methods 
We completed a retrospective review 
of patients at George Washington 
University Hospital, who experienced 
non-traumatic cardiac arrest and had 
POCUS with adequate views of the 
hepatic parenchyma. The majority 
of these images were sub-xiphoid 
eva luations of ca rd iac activ it y, 
with incidental capture of the liver. 
Archived ultrasound images were 
independently reviewed to determine 
the presence of hepatic parenchymal 
and/or hepatic venous air. Electronic 
medical records were then reviewed to 
collect other clinical data, including 
admission rate to ICU and overall 
hospital mortality. 
CONCLUSION 
Our study demonstrated that the 
incidence of post-arrest hepatic air 
on POCUS was common, although 
the presence of air in parenchyma 
alone did not signifcantly distinguish 
patients with respect to mortality. 
Hepatic venous air, however, may be 
of prognostic value as it could act as an 
indicator of mortality. Further studies 
Our study demonstrated that the incidence of Results 
From Jan. 1, 2017 post-arrest hepatic air on POCUS was common, th roug h June 16, 
2019, 87 patients 
although the presence of air in parenchyma m e t  i n c l u s i o n 
criteria, including 6 
In-hospital cardiac alone did not signifcantly distinguish patients 
arrests (ICHA) and 
81 out of hospital with respect to mortality. 
c a r d i a c  a r r e s t  
(OCHA) Ultimately, 68 (78.2%) died 
and 19 (21.8%) survived. Of those 
who died, 40 (58.8%) had hepatic air, 
while 28 (41.2%) had none. Of those 
who died with hepatic air, 38 (95%) 
demonstrated parenchymal air, while 
27 (67.5%) demonstrated venous air. Of 
the survivors, nine (47.4%) had hepatic 
air, while 10 (52.6%) had none. Only a 
single survivor demonstrated hepatic 
venous air (11%). While the diference 
in mortality with respect to presence 
of undifferentiated hepatic air was 
not signifcant (p=0.37), there was a 
signifcant diference with respect to 
the presence of venous air (p=0.0046). 
are necessary to better describe this 
phenomenon. 
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Sepsis remains a leading cause of death 
in the United States despite advance-
ments in early recognition and initi-
ating prompt treatment.1,2 Bandemia, 
defined as a band count >10%, is 
This data suggests that the clearance of 
bandemia can be used as a marker of clinical 
improvement in sepsis. It also shows that 
worsening bandemia is predictive of dete-
riorating clinical status and higher mortality. 
highly indicative of underlying infec-
tion and is increasingly being used 
in the emergency department (ED) 
and the intensive care unit (ICU) for 
identification of sepsis.3 Bandemia 
has been linked to worse outcomes, 
but its trend in the intensive care unit 
(ICU) is not well studied.4,5 In this 
retrospective study, we assessed the 
severity of bandemia at 0 and 72 hours 
among patients admitted to the ICU 
for sepsis or septic shock to evaluate if 
there was a direct correlation between 
increasing bandemia and clinical dete-
rioration among these patients. 
Methods 
We performed a retrospective chart 
review of patients admitted to our 
tertiary care ICU for sepsis or septic 
shock from the ED. Patients were 
excluded if their bandemia was due 
to etiologies other than sepsis. We 
recorded the band counts, Sequential 
Organ Failure Assessment (SOFA) 
scores, vasopressor use, and the 
clinical course of 134 patients included 
in our study at 0 and 72 hours after 
admission. Worsening clinical course 
was defined as increasing SOFA 
scores or the initiation and con-
tinuation of vasopressor support 
at 72 hours. Patients were analyzed 
based on SOFA trends (SG=SOFA 
group) and vasopressor 
trends (VG=vasopressor 
g r o u p).  T h e y  w e r e  
d i s t r i b u t e d  a m o n g  
groups 1-4 SG based on 
resolving, steady-state 
or worsen i ng SOFA 
scores, and groups 1–4 
VG based on improving, 
steady-state or wors-
e n i n g  v a s o p r e s s o r  
requirement. 
Results 
Among the 134 patients included 
for a na lysis, the average SOFA 
score on admission was 6. Based on 
SOFA scores and vasopressor trends 
between hour 0 and hour 72, there 
was a statistically signifcant improve-
ment in bandemia for patients in 
Group 1 (Range -10.3 ± 15.3, Mean 
-6) with resolving sepsis (P<0.0001 
SG, P<0.0001 VG) and a statistically 
significant worsening in bandemia 
(Range 10.1 ± 6.4, Mean 7) for patients 
in Group 3 with worsening sepsis 
(P=0.0001 SG, P=0.0007 VG). 
Conclusions 
This data suggests that the clearance 
of bandemia can be used as a marker 
of clinical improvement in sepsis. It 
also shows that worsening bandemia 
is predictive of deteriorating clinical 
status and higher mortality. The pres-
ence of bandemia and its trend in the 
ICU can, therefore, be used to guide 
the safe de-escalation of antibiotic 
therapy in the ICU, and potentially 
decrease the total duration of anti-
biotic use. 
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Septic shock is a common condition 
characterized by host immunodys-
regulation secondary to an infectious 
etiology leading to hypotension and 
lactic acidosis secondary to organ 
breakdown.1 Recent investigations sug-
gest that this dysregulation is biphasic, 
being initially a hyperimmune reaction 
resulting in systematic infammation 
followed by long term immunosup-
pression and associated sequalae.1 
Given that the major player in sepsis 
and septic shock is not the ofending 
pathogen but rather the response of the 
host immune system to that pathogen, 
it is crucial to develop a more robust 
understanding of the immune system’s 
essential role in this pathology and the 
role of conditions that modulate the 
immune system in the pathogenesis of 
sepsis, especially in vulnerable popula-
tions.1 Classically, and more commonly 
in adults, sepsis presents with decreased 
systemic vascular resistance (SVR) and 
warm extremities due to systematic 
endothelial disruption (warm shock), 
while pediatric cases tend to exhibit 
increased SVR and cold extremities 
(cold shock).2,3 However, in pedi-
atric populations with still maturing 
immune systems, the phenotype of 
septic shock is less understood. The 
purpose of this study was to evaluate 
diferent phenotypes of septic shock in 
a selected pediatric population. 
FIGURE: Beats per minute (BPM) and mean arterial pressure (MAP) in septic patients by age  
To do this, we created a case-
control study in which we followed the 
hospital courses of sixteen pediatric 
patients hospitalized at the Children’s 
National Hospital between 02/2018 
and 07/2019, eight of whom were 
admitted for septic shock and eight 
of whom were admitted for another 
condition to serve as a control. Care 
was taken to ensure that the control 
group did not include patients with an 
infammatory or infectious pathology 
or condition or had taken any immu-
nomodulatory medication to avoid any 
confounding data. The study patients 
were then further subdivided by age 
and key metrics, including gender, 
history of chronic illness, etiologic 
agent as determined by blood cultures, 
recurrent antibiotics use, oxygen 
saturation, erythrocyte sedimenta-
tion rate, C-reactive protein levels, 
white blood cell count, temperature, 
heart rate, and blood pressure. Due to 
the emergent nature of septic shock, 
there is an inevitable variation in the 
exact time of clinical presentation and 
therefore a spread in when specifcally 
our data was collected, however all 
data included within this study was 
collected within 24 hours of the pre-
sentation of initial symptoms of SIRS 
among children with septic shock. 
We observed that patients aged less 
than 12 years exhibited a septic shock 
phenotype distinct from patients 
over the age of 12. Patients with septic 
shock above the age of 12 had higher 
heart rates compared to control, 
while patients younger than 12 did not 
significantly from control (Figure). 
Furthermore, we found that mean 
arterial pressure (MAP) was signif-
cantly lower in children with septic 
shock older than 12 compared to their 
younger counterparts (Figure). These 
fndings could be due to fundamental 
diferences in the physiology of chil-
dren as compared to adults, such as 
the inability of children to modulate 
their cardiac contractility in the same 
manner as adults.2 This, in turn, is 
complicated by the decreased cardiac 
function commonly seen in pediatric 
septic shock.4 As such, in order to fur-
ther unravel the fundamental basis of 
Continued on p. 48 
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these phenotypes, future work will be 
focused on the extraction and isolation 
of peripheral blood mononuclear cells 
from each of the patients present here 
with the end goal of examining and 
characterizing the immunometabolic 
status of each of these patients.5 We 
hope that such an approach will help 
illuminate the fundamental principles 
underlying such observations, which in 
turn may prove crucial to developing 
novel methodologies for the treatment 
of sepsis. 
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Learning Objectives 
Refractory shock remains a challenge 
with nearly ubiquitous mortality. 
Novel therapies a re needed to 
m a i nta i n hemod y n a m ics when 
conventional mechanisms, have failed. 
Several exploratory therapies display 
potential efficacy in the literature, 
however it remains unclear which 
therapy is superior.1,2 We aim to clarify 
the efficacy of the current salvage 
therapies: Angiotensin II (ATII) vs 
Methylene Blue (MB) vs Vitamin C 
with thiamine and hydrocortisone 
( Vit C) for refractory shock. We 
hypothesize that these therapies will 
improve survivability and decrease 
the need for other vasopressors in 
patients with refractory shock. 
Methods 
This study is a retrospective review of 
patients with refractory shock started 
on ATII, MB, and/or Vit C in a single 
center mixed ICU. We collected base-
line demographics, shock etiology, 
APACHE II, mortality, etc. The pri-
mary outcome was mortality and the 
secondary outcome was the change 
in standard vasopressor requirements 
after initiation of these therapies. 
The groups were analyzed based on 
whether they received one intervention 
alone, or a combination of therapies. 
Results 
Fifty six patients were included in 
the ATII group, 21 patients in the 
MB group, and 114 in the Vit C 
group (total n= 191). As monotherapy, 
for those that received ATII (34) 
mortality was seen in 85.3% (29), for 
MB (9) mortality was seen in 77.8% 
(7), and for Vit C (79) mortality was 
seen in 51.9% (41). After adjusting 
for APACHE II, those who received 
ATII (monotherapy/combination) 
had 2.85 times higher odds of mor-
tality than those who did not receive 
the drug (CI 1.28 - 6.33, p=0.0103). Vit 
C, however, showed 65% lower odds 
of mortality when compared to those 
who did not receive it (aOR 0.35, CI 
0.14 - 0.87, p=0.0231). No statistical 
signifcance was seen for MB (aOR 
2.80, CI 0.53-14.78, p=0.2254). The 
vasopressor requirements decreased 
over the frst 24 hours after starting 
therapy with these drugs, but ATII 
still required higher doses of nor-
epinephrine and vasopressin com-
pared to Vit C (p=0.0011, p=0.0026 
respectively). 
Conclusion 
While these therapies have shown 
improvement in hemodynamics, this 
study questions the impact on overall 
mortality. These results could be due 
to the baseline low survivability in 
this patient population or due to not 
initiating these rescue therapies soon 
enough. More prospective studies are 
needed to further clarify their poten-
tial role in refractory shock. 
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Mohs micrographic surgery (MMS) 
is useful for treatment of melanomas 
located on specialty sites (head, 
neck, hands, feet, genitalia, pretibial 
leg), which have an increased risk 
of complications after conventional 
excision with post-operative margin 
assessment (CE-POMA).1 We previ-
ously reported local recurrence rates 
of 0.34% (2/597 lesions) for mela-
noma in situ (MIS) after MMS with 
melanoma antigen recognized by 
T-cells 1 (MART-1) immunostaining 
in a cohort of 563 individuals over 
a mean follow up of 2.8 years (0.01-
8.68 years).2 The same treatment 
technique for invasive melanoma, 
assessed in a larger cohort, yielded 
a local recurrence rate of 1.3% (7/556 
lesions).3 We now present our 11-year 
experience, which includes fve- and 
10-year follow up data. 
An IRB -approved retrospec- and previous treatment. Patients patients’ medical records or via tele-
tive cohort study was performed to were excluded if there was evidence phone call as previously described.1 
evaluate the local recurrence rates of locoregional or distant metastasis The primary outcome was biopsy-
of invasive and in situ melanomas at the time of surgery or clear margin proven local recurrence, defned as the 
treated using MMS with MART-1 status was not achieved using frozen presence of a new lesion in the surgical 
immunostaining at the University section interpretation alone (for scar where MMS was performed or 
of Pennsylvania between 2006 and example, cases for which MART-1 within 2 cm of the original lesion. 
2017. Data for all patients were pro- immunostaining was not reliable, Two thousand one hundred thirty-
spectively entered in an electronic such as desmoplastic melanoma, or four primary or locally recurrent inva-
database at the time of surgery and required additional tumor resection sive and in situ melanomas without 
includes patient demographics, tumor in the operating room). Follow up 
characteristics, anatomic location, information was obtained through Continued on p. 50 
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clinical evidence of metastasis were 
identifed in 1,973 patients. 186 cases of 
183 patients were excluded because 98 
patients declined to participate when 
consent was sought via telephone, 52 
patients were without clinic follow up 
and unable to be reached, 29 patients 
were deceased and without clinic 
follow up, and four patients required 
additional resection following MMS. 
Follow up information was available 
for a total of 1,790 patients with 1,948 
melanomas (Table).  
Six loca l recurrences (0.31%, 
6/1948) were identifed. The majority 
of lesions (5/6, 83%) that recurred 
were in situ and all lesions were 1 
cm or larger at the time of surgery. 
One-third (2/6) of recurrences were 
recurrent at the time of initial MMS. 
The average time to recurrence was 
1,347 days for MIS and 285 days for 
invasive melanoma. Five and ten-year 
minimum follow up information 
was available for 458 and 33 cases 
respectively. The five- and 10-year 
Kaplan–Meier local recurrence-free 
survival rates were 0.9946 (95% CI 
0.9855-0.9980) and 0.9856 (95% CI 
0.9490-0.9960) (Figure). 
The overa l l loca l recurrence 
rate was low (0.31%) and remained 
durable at five- and 10-year follow 
up, despite the majority of tumors 
located on specialty sites, which have 
FIGURE: Local Recurrence-Free Survival Rate 
an average local recurrence of ~10% 
following CE-POMA.2 All recur-
rences after MMS were located on 
the scalp, cheek, eyelid/conjunctiva, 
or foot, highlighting the challenges 
of treating specialty site melanomas. 
Our data support the use of MMS 
with MART-1 immunostaining to 
achieve durable local clearance for 
specialty site melanomas. 
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Since the early 2000s, there has 
been more than a 25-fold increase 
in the use of the robotic-assisted 
r a d i c a l  c y s t e c t o m y  ( R A RC )  
compared to more conventional, 
open radica l cystectomy (ORC) 
for bladder cancer.1 Proponents of 
this minimally invasive approach 
favor the decreased perioperative 
comorbidities associated with the 
modality, which includes decreased 
blood loss,  recover y t i me, a nd 
complication rates.2–4 Despite these 
advantages, the use of RARC has 
not gained the same popularity in the 
setting of higher grade malignancy, 
due to concerns of atypical recurrence 
from pneumoperitoneum-induced 
immunomodulation, tumor cel l 
intravasation and port-site trauma.5 
Recent randomized control trials, 
notably the R AZOR study, have 
d eter m i ne d  no  d i f f er ence s  i n  
oncologic or mortality outcomes 
compared to the open approach 
in bladder cancer as a whole, but 
have not sub-stratified by tumor 
aggressiveness.2,3 Given the putative 
mechanisms, likelihood of atypical 
recurrence would presumably be 
especially relevant in higher stage, 
FIGURE: Kaplan Meier for overall survival with median survival statistics for ORC and 
RARC 
locally advanced or node-positive 
disease, where the intrinsic metastatic 
potentia l of tumor cel ls may be 
greater. This study aims to compare 
the oncologic eff icacy of R ARC 
compared to ORC, among patients 
with stage pT3-4 or node-positive 
bladder cancer. 
Methods 
A retrospective cohort analysis of 
pT3-4N0-3 or pT(any)-4N1-3 patients 
who under went R A RC or ORC 
from 2010–16 was performed using 
the Nationa l Ca ncer Databa se 
(NCDB). Baseline demographic and 
clinicopathologic variables were 
compared between treatment cohorts. 
Primary outcome of overall survival 
was analyzed by way of Kaplan-Meier 
estimation with corresponding Log-
Rank test, followed by multivariable 
C o x - P r o p o r t i o n a l  H a z a r d s  
regression. Secondar y outcomes 
including 30-day mortality, 90-day 
mor ta l it y,  30 - day read m ission, 
positive margin status, receipt of 
adjuvant radiation or chemotherapy, 
and surgical inpatient length of stay 
were analyzed by way of Chi-square, 
Fisher’s exact, or Mann-Whitney U 
test, followed by multivariable logistic 
or transformed linear regression. 
Results 
There were 9,062 ORC cases and 
2,544 RARC cases that met inclusion 
criteria. RARC was significantly 
associated with superior unadjusted 
survival compared to ORC (Figure). 
Additionally, RARC was signifcantly 
associated with lower proportions 
of  u n adj u sted 30 - a nd 9 0 - d a y 
mortality, positive margin status, 
and shorter surgical inpatient stay 
Continued on p. 52 
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Outcome Open Robotic Adjusted Adjusted 
(n=9062) (n=2544) Hazard Ratio p 
(95% Cl) 
Overall Mortality 5954 1564 0.97 0.3239 
(65.7) (61.5) /0.92 - 1.03) 
Adjusted Odds 
Ratiof95% en 
30 Day Mortality 285 55 0.78 0.1113 
/3.2) /2.2) /0.58 - 1.06) 
90 Day Mortality 883 199 0.90 0.2137 
(9.9) r7.9) /0 .76 - 1.06) 
30 Day Unplanned Readmission 803 222 0.99 0.8618 
/8 .9) /8.8) /0.8 4 - 1.16) 
Positive Margin Status 1753 439 1.00 0.9652 
(19.8) (17.7) /0 .88 - I. 14) 
Adjuvant Radiation 333 79 0.97 0.8 169 
(3.8) (3.2) /0.75 - 1.26) 
Adjuvant Chemotherapy 2681 734 0.94 0.2306 
(30.7) /30. I) /0 .85 - 1.04) 
Adjusted 
In 18 /SE)! 
Surgica l Inpatient Stay (days) 8 7 -0.1025 <0.0001 • 
/6 11) (5 9) /0.0169) 
*=stat1st1cally s1gmficant, P <0.05; CI=confidence mteIVal; ln=natural loganthm; p=parameter estimate; SE=standard error; 
Note: For all comparisons, reference group= ORC 
Continued from p. 51 
(all respective P<0.05). However, 
after adjusting for confounding 
covariates (demographic variables, 
perioperative chemotherapy, clinical 
stage, pathological stage, clinical 
node status, and surgical margin 
status) multivariable analysis revealed 
no difference in mortality hazard 
or odds of seconda r y outcomes 
with the exception of inpatient stay 
(Table). RARC was also signifcantly 
associated with higher lymph node 
yield (increased incidence of >14 
lymph nodes examined relative to 
ORC; 55% vs. 40%; P<0.01). 
Conclusions 
RARC is no less safe than ORC for 
patients with locally advanced or 
node-positive bladder cancer on the 
basis of overall, 30- and 90-day survival 
outcomes. Unadjusted mortality and 
surgical outcomes in this population 
demonstrate advantages to the robotic 
modality. Perioperative benefits 
including shortened inpatient stay 
favor RARC, but further randomized 
control studies are necessary to better 
elucidate diferences between surgical 
approaches in this unique population. 
TABLE: Multivariate Analysis for Overall Mortality and Oncologic/Surgical Outcomes 
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Background/Objective 
Extensive resources are devoted to 
discovering novel cancer treatment 
modalities. Meanwhile, patient pri-
orities and experiences throughout 
their diagnoses and in the palliative 
care setting must also be addressed. 
Specifcally, among adolescents with 
cancer, patients’ defnitions of “living 
well” may elucidate treatment prefer-
ences, guide care teams and families, 
and infuence future behavioral inter-
ventions. The objective is to develop 
an empirical definition of “living 
well” for adolescents with cancer to 
enhance shared decision-making. 
Design/Methods 
Video recordings were analyzed from 
the Next Steps: Respecting Choices 
interviews with N=30 adolescents 
ages 14-21 years with cancer and their 
families, a subsample of N=126 ado-
lescent/family dyads participating in 
a randomized clinical trial, FAmily 
CEntered (FACE) Advance Care 
Planning. Videos were transcribed 
verbatim by the frst author who did 
not conduct the interviews. Using 
Krippendorf ’s inductive semantic 
content analysis, two authors created 
a codebook from two transcripts 
by identifying consistent themes.1 
Upon completion, the codebook was 
then used to independently code two 
additional transcripts to maximize 
the likelihood of code saturation. 
Coding proceeded of the remaining 
28 transcripts. Reconciliation was 
resolved by consensus to maximize 
reliability. Triangulation increased 
validity. 
Results 
“Living well” had four domains: (1) 
exercising autonomy over one’s total 
personhood; (2) participating in 
meaningful relationships with family 
and friends, in which shared experi-
ences are more important than the 
experiences themselves; (3) whole-
ness—emotional, physical, and spiri-
tual health; physical health includes 
nutritious eating and sleep hygiene; 
(4) living a productive life, engaging 
in meaningful activities, and living for 
more than your own interests. 
Conclusions 
By determining what “living well” 
means for adolescents with cancer, 
care teams and families can more 
easily understand patients’ priorities. 
A firm grasp on patients’ defini-
tions of “living well” could relieve 
signifcant burden from families and 
increase families’ willingness to honor 
adolescent treatment preferences. 
Findings may guide future psychoso-
cial interventions. 
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Characteristics n=41 
Age, years , (mean [SO}) 6L46 [17.08 ] 
G~d.er, male (%) 4L46 
Side, left (%) 36.59 
BMI (mean [SD]I) 26.17 [5.47] 
Length of follow up, years (mean 2.60 (1.36] 
rson 
SD: Standard dev1at1on; B:MI: Body mass mdex 
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Proximal humer us fractures are 
com mon or t hopaed ic i nj u r ies,  
constituting approx imately f ive 
percent of a l l fractures in some 
studies.1 These fractures exhibit a 
bimodal distribution; younger males 
sustain these injuries in higher energy 
mechanisms, while older females 
sustain these fractures with low 
energy falls.1 
Similar research has been done on 
clinical outcome measures following 
prox ima l humer us fract ures by 
Slobogean et al.,2 but their study 
had several notable differences. 
The cohort was smaller, limited to 
individuals over the age of 55, and 
included patients who underwent 
either operative or non-operative 
management. 
S p r o s s  e t  a l .  c o n d u c t e d  a  
retrospective review of 269 patients 
with surgically treated proximal 
humerus fractures and found older 
age to be a risk factor for worse 
clinical outcome scores in these 
patients.3 Unlike this study, the 
pres ent i nvest i g at ion a ss ess es  
patient reported outcomes using 
the American Shoulder and Elbow 
TABLE 1: TBaseline patient demographics 
Society Survey (ASES)4 and objective 
range of motion measurements in 
patients who underwent surgery for 
proximal humerus fractures 
Methods 
All proximal humerus fractures from 
September 2011 to February 2016 
treated at one institution by a single 
surgeon were reviewed under IRB 
#121615. Patients were contacted 
by phone or at a clinic follow up 
appointment to complete a validated 
clinical outcomes survey (ASES), 
which assesses diff icult y with a 
number of routine tasks involving 
the use of the afected shoulder. If 
patients had less than one year of 
clinical follow up they were asked 
to return to the office for range of 
motion evaluation. 
Results 
Of the 127 patients with qualifying 
injuries, 57 had greater than one year 
follow up and had completed the 
ASES survey. Sixteen patients were 
excluded because their index surgery 
was for a revision or non-union, or 
sufficient documentation was not 
available for analysis, leaving 41 
patients for evaluation in this study. 
Patient characteristics are shown in 
Table 1. The impacts of age, body mass 
index (BMI), and range of motion 
(initial and f inal) on ASES were 
examined in a univariate comparison 
using Pearson correlations (r), all of 
which were found not to be signifcant 
in predicting outcome (ASES) score 
(p>0.05 for all) (Table 2). 
Discussion 
Our data suggest that older patients 
are no more likely to fare worse than 
younger patients at least one year after 
surgery. While early range of motion 
is conventionally thought of as crucial 
to help avoid stiffness, we did not 
fnd that difculty with early passive 
range of motion was associated with 
unsatisfactory clinical outcomes. 
That is, even if patients lose range 
of motion in their injured shoulder, 
this does not signifcantly afect their 
quality of life. 
There are several limitations to 
this study. This is a retrospective 
study, and as such cannot determine 
the temporal association or causality 
of our outcomes of interest. Other 
pitfalls specifc to our outcomes of 
interest are inconsistency in range of 
motion measurements and diferences 
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n=41 Mean SD r p-va!ue 
ASES score 85_59 16_63 
Age, years 61-46 17_08 -0_03 0_87 
Brvrr 26_17 5-47 0_17 0_28 
Initial PROM, degrees 94_81 30_08 0_09 0_72 
Final Elevation, degrees 141-20 25-75 0-21 0_90 
Final External Rota tion, degrees 53-95 10_65 0_13 0_78 
Final Internal Rotation, degrees 7_81 1-36 -0_09 0_68 
ASES: Amencan Society of Shoulde r and Elbow Surgeons; SD: standard dev1at1on; 
BMI: body mass index; PROM: passive range of motion_ 
in patient response rates that also are 
associated with outcomes of interest. 
Conclusion 
Counseling patients on their functional 
prognosis following a traumatic injury 
is challenging. While existing evidence 
suggests that older patients are likely to 
have worse outcomes, our study suggests 
that it is not clear that older patients are 
at risk of worse self-reported outcomes 
than younger patients one year after 
surgical treatment for fractures of the 
proximal humerus. 
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During the past decades, frame-
based stereotactic radiosurgery, and 
Gamma Knife® in particular, has 
demonstrated its efcacy and safety 
as therapy for Trigeminal Neuralgia 
(TN).1 However, few studies exist 
using non-frame-based radiosurgery 
devices such as CyberKnife (CK), 
especially those that report long-term 
follow-up. Our primary objective in 
this study is to evaluate the long-term 
efectiveness of CK stereotactic radio-
surgery on TN pain response. 
From 2010 to 2019, 38 patients 
were treated for symptomatic trigem-
inal neuralgia at Virginia Hospital 
Center: 68.4% patients were female, 
mean age was 72.3 years-old (range, 
30 – 93). We performed a retrospec-
tive chart-review of these patients in 
order to collate predefned variables, 
followed by a prospectively collected 
follow-up phone survey to collect 
most recent health data. CK out-
come was measured using the Barrow 
Neurological Institute (BNI) scores 
for pain and hypoesthesia, which was 
statistically evaluated by univariate 
and multivariate analyses. We con-
sidered a successful CK treatment 
as a decrease in BNI pain score from 
pre-treatment to follow-up. 
CK treatment was initially suc-
cessful in 87.5% of patients, with 
time to max pain relief ranging from 
three weeks to 36 weeks (mean, 10.5 
weeks). Continued success at most 
recent follow-up was reported in 
81.3% of patients (mean follow-up, 
37.1 months). The median pre-treat-
ment BNI pain score was V and the 
median BNI pain score at most recent 
follow-up was IIIa, indicating an 
improved quality of life. Trigeminal 
pain recurred in 18.8% of patients 
(range, 1.3 – 2.0 years). New-onset 
bothersome trigeminal hypoesthesia 
(defned as BNI hypoesthesia=II/III) 
was reported in 68.6% of patients. 
Increased CK success was found to 
correlate with increased BNI hypo-
esthesia scores (p=.001) as well as 
with increased side effects such as 
Continued on p. 56 
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dysphagia and paresthesia. (p=.003). 
Additionally, increased CK suc-
cess was found to correlate with an 
idiopathic pathogenesis of TN pain 
in comparison to TN pain derived 
from stroke/tumor/surgery (p=.034). 
Interestingly, CK success did not 
correlate with typical nor atypical TN 
classifcation. 
Our results demonstrate that CK 
stereotactic radiosurgery is an efec-
tive long-term therapy for treating 
TN. However, patients should be 
aware that such symptoms as hypo-
esthesia, paresthesia, and dysphagia 
can occur that correlate with an 
effective treatment. Furthermore, 
TN pathogeneses should be taken 
into account to be used as a possible 
FIGURE: Bar graph of BNI scores 
predictor of success during CK treat-
ment planning. 
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The primary treatment of adductor 
spasmodic dysphonia is repeated 
injections of Botulinum toxin type 
A (Botox) into the thyroarytenoid 
muscles.1 Dosing can be performed 
into either one or both thyroarytenoid 
muscles.2 The objective of this study 
is to evaluate the treatment efect and 
side efect profle across a large number 
of injections. A study with the same 
objective was performed previously 
in 2002 on 45 patients.2 This current 
study is a retrospective study of all 
Unilateral Bilateral Chi-Squared 
Optimal Effect 47% 55% p= 0 000 
Optimal Side Effect 77% 73% p= 0 023 
Optimal Effect/Side Effects 33% 36% p= 0 0228 
FIGURE: Chi-Square Analysis of Those Injections Resulting in an Optimal Effect of three 
Months or Greater and an Optimal Side Effect Duration Less Than or Equal to two Weeks  
patients with adductor spasmodic 
dysphonia with or without tremor 
treated by the senior laryngologist at 
The George Washington University. 
In the current study, 272 patients (214 
females and 58 males) were included 
in the analysis. Duration of effect 
and side efects (vocal weakness and 
liquid dysphagia) after each injection 
were recorded into a database. This 
data was analyzed using Chi-square 
analysis. A total of 4023 injections 
(2708 bilateral and 1315 unilateral) 
w er e  e v a l u ate d  i n  t h i s  st ud y.  
Optimal effect duration ( greater 
than or equal to three months) was 
more commonly seen in the bilateral 
injection patients (55%) compared 
to the unilateral injection patients 
(47%) with a p=0.0001. Optimal side 
efect duration (less than or equal to 2 
weeks) was also better for the bilateral 
injection patients (73%) compared 
to the unilateral injection patients 
(77%) with a p=0.023. Having both 
optimal efect and side efect in the 
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same injection was more commonly 
seen in the bilaterally injected patients 
(36%) compared to the unilateral 
patients (33%) with a p=0.0228. This 
study shows that bilateral injections of 
Botox are more efective in producing 
optimal efect/side efect profles. 
REFERENCES: 
1. Patel PN, Kabagambe EK, Starkweather 
JC, et al. Outcomes of onabotulinum 
toxin a treatment for adductor spasmodic 
dysphonia and laryngeal tremor. JAMA 
Otolaryngol HNS. 2018;144(4):293-9. 
2. Bielamowicz S, Stager SV, Badillo A, 
Godlewski A. Unilateral versus bilateral 
injections of botulinum toxin in patients 
with adductor spasmodic dysphonia. J 
Voice. 2002;16(1):117-23. 
Effect of Premedication with Midazolam on Recovery and 
Discharge Times After Tonsillectomy and Adenoidectomy 
Andrew Garcia, 
MSII 
ADVISORS: 
Claude Abdallah 
MD, MSc, FASA1 
1Department of 
Anesthesiology, 
Children’s National Medical Center 
Midazolam premedication is widely 
used before general anesthesia, but 
remains controversial due to its 
paradoxical side effects, including 
over sedation, decreased blood pres-
sure, and respiratory depression. 
Patients with obstructive sleep apnea 
(OSA) are at particularly high risk 
for upper airway collapse as result of 
worsened obstruction of the pharynx 
after administration of sedatives, 
anesthetics, and analgesics.1 While 
professional guidelines, including 
those from American Society of 
Anesthesiologists, provide direction 
regarding the perioperative manage-
ment of OSA patients, focusing on 
general risks of respiratory depres-
sion and airway collapse with seda-
tives and opioids, specifc guidance 
with regards to midazolam on emer-
gence and recovery time in pediatric 
patients with moderate to severe 
OSA undergoing tonsillectomy and 
adenoidectomy (T&A) is limited.2 
We hypothesized that preoperative 
TABLE 1: Demographic characteristics by midazolam status 
December 2015. Patients who received 
midazolam were compared to patients 
who did not receive midazolam. 
Demographic data included age, 
gender, apnea-hypopnea score, body 
Continued on p. 58 
Characteristics 
Midazolam 
P value 
No (n=387) Yes (n=83) 
Age, mean (SD) 3 7 (1 4) 3 4 (1 4) 0 14 
Weight, mean (SD) 17 4 (7 8) 16 5 (6 3) 0 31 
BMI, mean (SD) 16 9 (3 9) 16 8 (3 9) 0 88 
Gender
 Male 212 (54 8%) 51 (61 4%) 0 27
    Female 175 (45 2%) 32 (38 6%) 
Race
 African Am /Black 187 (48 4%) 29 (34 9%) 0 16
    Caucasian 66 (17 1%) 18 (21 7%)
 Hispanic/Latino 92 (23 8%) 24 (28 9%)
 Other 41 (10 6%) 12 (14 5%) 
Awake or Deep
    Awake 68 (17 6%) 11 (13 3%) 0 34
 Deep 319 (82 4%) 72 (86 7%) 
ASA score
 1 56 (14 5%) 14 (16 9%) 0 41
 2 295 (76 4%) 65 (78 3%)
 3 35 (9 1%) 4 (4 8%) 
*P values were obtained from t-test for continuous data, and Chi-square test for 
categorical data 
midazolam may increase emergence 
and discharge times in pediatric 
patients with OSA after T&A. 
We conducted a retrospective 
chart review of patients at Children’s 
National Health System who under-
went T&A between July 2014 and 
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Group 
Mean emergence time 
(95% CI), min* 
Difference 
(95% CI), 
min 
P value 
Mean discharge time 
(95% CI), min* 
Difference 
(95% CI), 
min 
P value 
No Midazolam 45 1 (39 9, 50 2) 5 2 
0 41 
115 8 (108 8, 122 9) 10 1 
(-6 7, 26 8) 
0 24 
Midazolam 50 3 (39 2, 61 4) (-7 1, 17 4) 125 9 (110 7, 141 1) 
TABLE 2: Emergence time, discharge time between Midazolam vs  No Midazolam group 
Continued from p. 57 
mass index, diagnosis, American 
Society of Anesthesiologists physical 
status classifcation score, length of 
surgery, and medications adminis-
tered for anesthesia and recovery. 
Data endpoints included emergence 
and discharge times, perioperative 
desaturations, postoperative apneic 
episodes and delirium. Baseline 
demographic characteristics were 
compared using unpaired t-test for 
continuous data and Chi-square test 
for categorical data. Emergence and 
discharge times were compared using 
multiple linear regression, adjusting 
for predefned potential confounding 
factors. 
There were no signifcant difer-
ences in demographic characteristics 
between the Midzolam (n=83) and No 
Midazolam (n=387) groups. Likewise, 
there were no signifcant diference 
in emergence or discharge times 
between these two groups. After 
adjusting for all potential confounders 
(surgery duration, dexmedetomidine 
and fentanyl doses adjusted to weight, 
and awake or deep tracheal extuba-
tion status), emergence time was 5.2 
minutes (95% CI: -7.1, 17.4) longer in 
the Midazolam group (50.3 minutes, 
95% CI: 39.2, 61.4) compared to the 
No Midazolam group (45.1 minutes, 
95% CI: 39.9, 50.2). This association 
was not statistically significant (P= 
0.41). After adjusting for potential 
confounders (surgery duration, dex-
medetomidine and fentanyl doses 
dose adjusted to weight), discharge 
time was 10.1 minutes (95% CI: -6.7, 
26.8) longer in the Midazolam group 
(125.9 minutes, 95% CI: 110.7, 141.1) 
compared to the No Midazolam 
group (115.8 minutes, 95% CI: 108.8, 
122.9). This association was not sta-
tistically signifcant (P= 0.24). 
Premedication with midazolam 
was not associated with a prolonged 
emergence or discharge time or with a 
higher incidence of complications after 
anesthesia for T&A in patients with 
OSA. These data can help to further 
characterize the best perioperative 
management strategies in pediatric 
patients with OSA undergoing T&A. 
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TABLE 1: Pre-operative indomethacin treatment and post-operative neurological 
Indomethacin 
Post-operative neurological fndings 
(IVH, PLV, ventriculomegaly, RI values) 
N = 54 Better Mixed Same Worse Missing 
Yes n = 17 8 (47 1%) 0 (0 0%) 7 (41 2%) 0 (0 0%) 2 (11 8%) 
No n = 37 15 (40 5%) 3 (8 1%) 9 (24 3%) 4 (10 8%) 6 (16 2%) 
Washington University, School of Medicine and 
fndingsHealth Sciences 
2Children’s National Hospital 
Patent Ductus Arteriosus (PDA) is a 
congenital heart defect that afects 
about half of preterm infants born 
before 32 weeks of gestation. When 
pharmacotherapy with cycloox y-
genase inhibitors like indomethacin 
is unsuccessful or contraindicated, 
patients must undergo surgical liga-
tion of ductus arteriosus.1 However, 
surgical ligation is signifcantly asso-
ciated with neurodevelopmental 
impairment (NDI) at two years of 
age.2 Examples of NDI range from 
cerebral palsy to compromised vision, 
hearing, posture, language, cognition, 
socialization, and coordination. In 
addition, patients who underwent sec-
ondary surgical ligation demonstrated 
higher NDI compared to those who 
received indomethacin treatment 
alone.1 
Neurological fndings leading to 
motor and cognitive delay in preterm 
infants include intraventricular hem-
orrhage (IVH), periventricular leu-
komalacia (PVL), ventriculomegaly, 
and hydrocephalus. Severity of the 
frst three presentations can be deter-
mined via diferent grading systems 
based on head ultrasounds (HUS) 
and magnetic resonance imaging 
(MRI). Importantly, the higher the 
IVH or PVL grade, the higher the 
risk for ventriculomegaly as well 
as nonoptimal neurodevelopment. 
Furthermore, a progressive elevation 
in intracranial pressure (ICP) seen in 
hydrocephalus demonstrates a strong 
correlation with increased resistive 
index (RI) values of anterior cerebral 
artery (ACA), which is measured via 
Dopper.3 In fact, infants with PDA 
exhibited higher RI values than 
those without PDA. But among those 
who received surgical 
ligation, there was no 
significant difference 
between pre- and post-
operative RI values.4 
O u r o b j e c t i v e s 
were to deter m i ne 
the clinical compli-
ance with pre-oper-
ative indomethacin 
treatment as well as 
post-operative neu-
rodevelopmental screening and con-
sultations. Given that the risk for 
NDI is higher with surgical ligation, 
an understanding of the current 
screening methodology is needed for 
improvement of care. 
A three-year retrospective chart 
review of premature infants who 
received PDA ligation at Children’s 
National Hospital was performed. 
Information regarding pre-operative 
indomethacin use and post-operative 
consultations in neurology, child 
development, and physician medi-
cine and rehabilitation ( PM&R) 
were extracted from the charts. 
Neurological imaging data from HUS, 
Doppler, and MRI were re-evaluated 
for IVH, PVL, cerebellar hemor-
rhage, ventricular dilation, and RI 
values. Standard statistical method-
ology was applied. 
[P]ost-operative consultations and screening 
measurements revealed that a majority 
of patients who underwent PDA ligation 
present with symptoms concerning for poor 
neurodevelopmental outcomes. 
Fifty-four patients were identifed 
(27M/27F; mean [SD] gestational age 
25.2 [2.74] weeks). Of these patients, 
all seven infants (13.0%), who demon-
strated worse or mixed postoperative 
fndings in terms of RI values and ven-
triculomegaly, had not received indo-
methacin prior to surgical ligation 
(primary ligation) (Table 1). In two of 
Continued on p. 60 
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those patients, indomethacin was con-
traindicated because of evolving IVH 
and/or coagulopathy. Additionally, 32 
infants (59.3%) received postoperative 
consultations in child development, 
neurology and/or PM&R; the other 
22 infants did not have them on fle. 
Out of the 32 cases, 29 infants (90.6%) 
exhibited developmental delay and/ 
or neurological abnormalities on 
their frst visits. Only three patients 
(9.4%) developed normally across all 
domains and lacked any signifcant 
neurological abnormalities after PDA 
ligation (Table 2). 
In conclusion, the retrospective 
chart review demonstrated a potential 
correlation between the lack of pre-
operative indomethacin treatment 
and worse or mixed neurological fnd-
ings after PDA ligation. Additionally, 
post-operative consultations and 
screening measurements revealed that 
a majority of patients who underwent 
First postoperative consultations 
(child development, neurology, PM&R) 
n = 32 
Developmental delay ± neurological abnormalities 29 (90 6%) 
Normal development without 
neurological abnormalities 
3 (9 4%) 
TABLE 2: Neurodevelopmental fndings based on frst post-operative consultations 
PDA ligation present with symptoms 
concerning for poor neurodevelop-
mental outcomes. Although preterm 
infants selected for surgical ligation 
may have a higher pre-ligation risk 
for NDI,1 the reported prevalence of 
neurodevelopmental abnormalities 
may also be underestimated due to the 
lack of post-operative screening and 
follow-ups. Thus, the study highlights 
the need for a better neurodevelop-
mental screening protocol for preterm 
infants receiving PDA ligation. 
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FIGURE 1: Cold Atmospheric Plasma and The Activation State 
(a) Plasma is the fourth state of matter  (b) Cold atmospheric plasma is generated by 
passing a carrying gas through high voltage to generate an array of emitted ionized 
particles  (c) Short treatment with cold atmospheric plasma sensitizes cancer cells to 
chemotherapy to generate an activation state  
Glioblastoma multiforme (GBM) 
is the most common and aggressive 
primar y centra l ner vous system 
(CNS) neoplasm in adults. Diagnosis 
with GBM confers a dismal prognosis 
due to four main characteristics of 
the malignancy: (1) extensive prolif-
erative, angiogenic, migrative, and 
invasive capabilities that result in an 
incredibly tolerable tissue, (2) micro-
invasion limiting the ability to per-
form gross total surgical resection, (3) 
a heterogeneous cell population that 
responds diferentially to treatment 
within the same mass, and (4) down-
regulation of the immune system 
in the tumor microenvironment, 
enabling immune evasion. The cur-
rent standard of care for the treatment 
of GBM includes a combination of 
radiation therapy, surgical resection, 
and medical management (temozolo-
mide/TMZ at initial presentation and 
bevacizumab at recurrence). With a 
median post-diagnosis survival time 
of 15–16 months in patients receiving 
multifaceted treatment (chemo-
therapy, radiation, and surgery), any 
innovation with the potential to 
either independently target or syn-
ergistically improve other, currently 
available treatment modalities for 
GBM is of great interest to neuro-
oncology providers and patients. 
Cold atmospheric plasma (CAP) 
is a high energ y ionized state of 
matter (Figure 1A) that can be applied 
directly as a microjet or indirectly as 
an injection to tissue (figure 1B) as 
a means of immediately and selec-
tively sensitizing cancer cells to 
chemotherapeutics.1,5 The maximum 
threshold of sensitization, termed 
the “activation state”, can be reached 
within 20 seconds of CAP treat-
ment (Figure 1C). De-sensitization, 
however, takes fve hours after CAP 
treatment.2,3 By applying an electrical 
feld to a carrying gas (usually helium 
Continued on p. 62 
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or argon), CAP is thought to exert its 
anti-cancer efects by generating reac-
tive oxygen and nitrogen species that 
selectively damage neoplastic cells 
due to their pre-existing oxidative 
stress from high metabolic activity.4 
In this study we demonstrate the 
existence of a CAP-induced activa-
tion state among human glioblastoma 
(U87) cells which confers increased 
sensitivity to TMZ and reactive spe-
cies from H2O2 as quantifed via cell 
viability. 
Methods 
The CAP device was designed and 
assembled in the Keidar lab at the 
George Washington Universit y. 
This device used helium as the car-
rying gas at a fow rate of 8L / min. 
Electrodes were connected to a high 
voltage resonant transformer (8 kV 
peak to peak, 12.5 Hz). Optical emis-
sion spectroscopy was used to char-
acterize the plasma. U87 cells were 
cultured in DMEM supplemented 
by 1% penicillin/streptomycin and 
10% FBS. CAP was delivered to U87 
cells in a 96-well plate for 1 minute in 
combination with 10 µM H2O2, 15 µM 
H2O2, 10 µM TMZ, or 50 µM TMZ 
in a total volume of 50 µL of media 
during treatment. Cell viability was 
measured by a standard MTT assay 
and the Cell Titer Glo 2.0 luminescent 
assay after three days of incubation. 
Results 
Direct treatment with CA P for 
60 seconds sensitized U87 cells to 
FIGURE 2: Cell Viability After Treatment in the Activation State 
(a) Schematic of the experiment  Cell viability after treatment with (b) TMZ and (c) TMZ 
+ CAP 
treatment with TMZ at concentra-
tions of 10 µM and 50 µM (Figure 2). 
Conclusions 
Treatment of U87 cells with CAP 
produced an activation state that 
sensitized cells to treatment by H2O2 
and TMZ. This drastic increase in 
cytotoxicity from a widely used drug 
provides encouraging evidence to 
support further research and the pos-
sible clinical application of CAP as an 
adjunct to existing therapy for GBM. 
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Few models to train fascial closure 
are currently available. Cadaveric or 
porcine fascia based training is not 
ideal due to signifcant inter-specimen 
variability, low supply, cost, and eth- TABLE: Qualitative survey evaluating synthetic fascia characteristics (n= number of 
ical concerns. We aimed to create an surgeons) 
inexpensive and easily manufactured 
synthetic fascia suitable for simula-
tion-based fascial closure training. qualitatively evaluated by ten sur- 16 hour curing time. 9/10 surgeons 
Characteristic 
Similar to Human 
Fascia 
Stronger 
pull-through 
force/ larger 
needle hole 
Weaker 
pull-through 
force/ smaller 
needle hole 
Needle hole 
enlargement 
9 - 1 
Suture-pull through 4 6 -
Similar to Human 
Fascia 
Somewhat 
similar to 
Human Fascia 
Not similar to 
Human Fascia 
Response to cutting 4 5 1 
Tactile Feel (upon 
palpation) 
- 7 3 
Drag of needle 3 6 1 
Grasping behavior 
(with Kocher clamps 
and forceps) 
3 5 2 
geons experienced in fascial closure. rated the construct as an acceptable Methods 
Respondents were instr ucted to teaching tool for abdominal fascial 
Synthetic fascia constructs were create four 3cm incisions and grasp closures with only one respondent 
manufactured using combinations of the fascia with a Kocher clamp and stating the construct felt “unnatural”. 
various silicones and mesh materials. toothed forceps. Incisions were then The table below shows the breakdown 
Constructs were biomechanically closed with 2-0 polypropylene and of responses for each performance 
evaluated via tensile suture pull- 1 polydioxanone sutures, using both characteristic. 
through testing. Iterative testing 1cm bites/1cm advancement and 5mm 
provided direction for each fascia Conclusions bites/5 mm advancement techniques. 
construct with the goal of achieving We describe a synthetic fascia con-
pull-through forces within 10N of Results struct that is inexpensive, easily man-
the average strength of porcine fascia. The optimized synthetic fascia was ufactured, mimics the biomechanical 
Each construct was qualitatively created using a combination of sili- profle of porcine fascia, and performs 
assessed by the surgeon authors cone and powermesh with material similar to human fascia as assessed 
to optimize the tactile feel, suture cost for one 24x24cm sheet of $4.09 by a group of experienced surgeons. 
drag, and thickness compared with and a one-time cost for mold creation Its use in simulation-based training 
human fascia. The construct with of $50. Manufacturing time for each should be encouraged and outcomes 
the best biomechanical profile was fascial sheet was 20 minutes with a measured. 
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Distal radius fractures are the most 
common long bone fracture in the 
pediatric population and frequently 
requ i re ca sti n g for treatment.  
Traditional casts are heavy, bulky, 
susceptible to water damage, and 
frequently lead to cutaneous and 
n e u r o v a s c u l a r  com pl i c a t ion s .  
The incidence of cast-related skin 
complications is approximated to 
be 13.6 per 1,000 patients.1 Current 
3D laser sca nning a nd printing 
tech nolog y en ables phy sicia n s 
to take 3D images of a limb and 
create a customized, biocompatible 
cast that is lightweight, thin, and 
waterproof. Chen et al. have shown 
that 3D-printed casts of distal radius 
fractures have comparable clinical 
effectiveness compared to plaster 
casts.2 Here we have developed a 
c ustom ized a nd biocompatible 
3D-printed cast that can be used for 
treatment of minimally displaced 
distal radius fractures in pediatric 
patients. 
Methods: 
The forearm of a sample patient was 
scanned using the handheld Artec Eva 
Lite 3D scanner. The 3D image was 
uploaded into Geomagic and used to 
create a two-piece hollow-shell cast 
A B 
FIGURE: A, the dorsal view of the 3D-printed cast  B, the lateral view of the 
3D-printed cast 
with computer assisted design (CAD). cast was ofset from the skin of our 
The fles were then sent to Xometry®, sample patient by 1.75mm to allow 
a 3D-printing company, to be printed for expected post-traumatic tissue 
u si n g M E D610 bio compat ible edema and prevent compartment 
m ater i a l  (a  d u r a ble  
polymer-based material 
approved by the FDA for 
prolonged skin contact). 
The cast was designed 
in two pieces to allow 
for easy placement on 
the forearm. Zip ties 
were used to enclose the 
cast around the forearm 
circumferentially. Holes 
w e r e  i n t e n t i o n a l l y  
printed in the design to allow for 
facile evaporation of water and sweat. 
Results: 
A  3 D - pr i nte d  c a s t  ( Fi g u r e  A  
and B) was printed on MED610 
biocompatible material according 
to our specifcations obtained from 
the Artec® Eva Lite 3D scanner. The 
thickness of the cast was 5 mm. The 
Current 3D laser scanning and printing 
technology enables physicians to take 3D 
images of a limb and create a customized, 
biocompatible cast that is lightweight, thin, 
and waterproof. 
syndrome. Our sample patient wore 
this cast for two days (removed for 
showering and sleeping) and did not 
have any cutaneous or neurovascular 
complications. 
Conclusions 
I n t h i s  work ,  we s ucces sf u l l y  
d e v e l o p e d  a  c u s t o m i z e d ,  
biocompatible 3D-printed forearm 
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cast with the potentia l to treat 
minimally displaced radius fractures 
in orthopedic pediatric patients. Our 
future research will assess the clinical 
efectiveness and rate of cutaneous 
and neurovascular complications 
with the use of the cast compared to 
traditional casts in children aged 5 to 
12 with minimally displaced radius 
fractures. These studies will provide 
a foundation for clinical trials to test 
the efectiveness of our 3D-printed 
casts in treating injuries requiring 
prolonged immobilization. 
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